PREDICTIVE POWER OF CRIB-II AND SNEPPE-II IN MORTALITY RISK OF EARLY PRETERM NEONATE AND/OR LOW BIRTH WEIGHT

BY

Dr.ANUJA.T.

Dissertation submitted to

BLDE (Deemed to be University) Vijayapur, Karnataka



In partial fulfillment of the requirements for the degree of

DOCTOR OF MEDICINE

IN

PEDIATRICS

Under the guidance of

Dr.M.M.PATIL

PROFESSOR

DEPARTMENTOF PEDIATRICS

BLDE (Deemed to be University)
SHRIB.M.PATILMEDICALCOLLEGE

HOSPITAL & RESEARCH CENTRE, VIJAYAPUR

KARNATAKA

2020

"PREDICTIVE POWER OF CRIB-II AND SNAPPE-II IN MORTALITY RISK OF EARLY PRETERM NEONATE AND/OR LOW BIRTH WEIGHT"

DOCTOR OF MEDICINE IN **PEDIATRICS**

ABBREVATIONS

NICU - Neonatal Intensive Care unit

CRIB - Clinical Risk Index of Babies

CRIB II - Clinical Risk Index of Babies II

SNAP - Score for Neonatal Acute Physiology

SNAP II - Score for Neonatal Acute Physiology II

SNAPPE - Score for Neonatal Acute Physiology with Perinatal Extension

SNAPPE II - Score for Neonatal Acute Physiology with Perinatal Extension II

ABG - Arterial Blood Gas

MBP - Mean Blood Pressure

GA – Gestational Age

BW - Birth Weight

ELBW – Extreme Low Birth Weight

VLBW – Very Low Birth Weight

LBW - Low Birth Weight

POG – Period of Gestation

PIH – Pregnancy Induced Hypertension

UO – Urine Output

BP – Blood Pressure

NBS – New Ballard Score

ABSTRACT

BACKGROUND:

Recently, there have been a significant increase in preterm and LBW neonates brought to

Neonatal intensive care units. These neonates need specific attention and need to be thoroughly

evaluated because they were born with high clinical risks. Therefore, it is crucial to classify the

newborns according to gestational age and birth weight as soon as they are admitted, plan clinical

interventions, anticipate outcomes, schedule follow-up visits accordingly, and determine the

amount of clinical care that will eventually be required. Significant, diligent initiatives have been

taken in recent years to lower neonatal mortality. The mortality of neonates has been evaluated

using a variety of grading methods.

OBJECTIVES

To evaluate the CRIB-II and SNAPPE II questionnaires' capacity to detect neonatal

mortality in early preterm and/or low birth weight neonates admitted to the NICU.

TYPE OF STUDY: Prospective Observational Study

STUDY PERIOD: Period of 18 months, from Jan 2021 to June 2022.

3

STUDY POPULATION:

All neonates admitted to LEVEL III-A Neonatal Intensive Care Unit (NICU), BLDE (Deemed to be University, Shri B. M. PATIL MEDICAL COLLEGE HOSPITAL AND RESEARCH CENTRE, VIJAYAPUR, KARNATAKA who meet the inclusion criteria.

METHODOLOGY:

Neonates fulfilling the inclusion criteria were enrolled in the study. Neonatal data in preference to CRIB II and SNAPPE II were documented. Parameters are birth weight, gestational age, gender, temperature, APGAR @ 1 minute and 5 minutes, need for resuscitation at birth, if any, blood pressure (MAP), seizures, and urine output. Neonatal outcome at the time of discharge was assessed.

RESULTS:

A total of 324 neonates in the study group, 283 survived, and 33 not survived, with a mean gestational age of 32 weeks and a birth weight of 1760 grams. Baseline maternal and neonatal characteristics were not significant. SNAPPE II had better mortality predictive in neonates with 78% sensitivity and 82% specificity in neonates born before 34 weeks with a statistically significant p-value (<0.05). CRIB II score had good mortality predictive ability for neonates less than 32 weeks only with a sensitivity of 64% and specificity of 74%. Individually birth weight and gestational weeks were not good predictors of neonatal mortality.

CONCLUSION:

SNAPPE II score is an appropriate means for predicting the outcome of mortality in

very low birthweight and in neonates 28-32 weeks . In preterm newborns, SNAP PE II score is

a more accurate predictor of neonatal mortality than CRIB II score. CRIB II and SNAPPE II

both are better predictors of mortality outcome in comparison to birth weight and gestational

age independently.

KEYWORDS: SNAPPE II, CRIB II, Neonates, Mortality Predictor, Preterm, LBW

5

TABLE OF CONTENTS

Sl No.	Contents	Page No.
1	INTRODUCTION	17
2	AIMS AND OBJECTIVES	19
3	REVIEW OF LITERATURE	20
4	METHODOLOGY	69
5	RESULTS	74
6	DISCUSSION	114
7	LIMITATION	120
8	CONCLUSION	124
9	BIBILOGRAPHY	125
10	ANNEXURES	
	1. ETHICAL CLEARENCE CERTIFICATE	131
	2. CONSENT FORM	132
	3.PROFORMA	137
	4.MASTER CHART	144

LIST OF TABLES

SI No	PARTICULARS	Page No
1a	Birthweight And Gestational Age Of Neonates	74
1b	Gestational Age Of Neonates	75
1c	Birthweight Of Neonates	76
1d	Sex Distribution Of Neonates	77
2	Mode Of Delivery	78
3	Baseline Maternal Factors Between Neonatal Groups	80-81
4	Summary Of Neonatal characteristics	82
5	Comparison Of Various Neonatal Variables Between Two Groups	83
6a	Comparison Of Birthweight Between Different Groups	84
6b	Comparison Of POG Between Different Groups	85
6с	Outcome of Neonates by Gender	86
7	Comparison Of CRIB II & SNAPPE II scores between two groups	87
8	Comparison Of Clinical And Laboratory Parameters Between Two Groups	88
9a	Comparison of scores BW <1000g	90
9b	Comparison of scores BW 1000 – 1500g	91
9c	Comparison of scores BW 1500 – 2000g	92
9d	Comparison of scores BW 2001 – 2499	93

10	Area Under the Curve – Birthweight	94
11	Area Under the Curve – Gestation	95
12	Area Under the Curve – CRIB II	98
13	Area Under the Curve – SNAPPE II	99
14	Area Under the Curve – (1000-1500g) SNAPPE II, BW, Gestational period, CRIB II	104
15	Area Under the Curve – (<1000g) SNAPPE II, BW, Gestational period, CRIB II	108
16	Area Under the Curve – (1500-2000g) SNAPPE II, BW, Gestational period, CRIB II	110
17	Comparison of GA between CRIB II & SNAPPE II	112
18	Comparison of Birthweight between CRIB II & SNAPPE II	113

LIST OF FIGURES

Sl No	PARTICULARS	Page No
1	Ballard Scoring	26
2	Reliability Of Dubowitz & Ballard Score	27
3	New Ballard Scoring	31
4	CRIB II Score	35
5	Oxygen Dissociation Curve Of Fetal Hb Vs Adult Hb	48
6	Oxygen Dissociation Curve Of Neonates	48
7	Effect Of temperature & pH On Oxygenation Dissociation Curve	49
8	APGAR Score	50
9	MAP at different BW -10 th percentile	54
10	NIBP measurement in neonate	54
11a	Gestational Age Of Neonates	75
11b	Birthweight Of Neonates	76
11c	Sex Distribution Of Neonates	77
12	Mode Of Delivery	78
13a	Maternal Gravida Status	81
13b	Baseline Maternal Factors Between Neonatal Groups	82
14	ROC – Birthweight	95
15	ROC – Gestation	96
16	ROC – CRIB II	98

17	ROC – SNAPPE II	101
1.0		100
18	ROC – Comparing all parameters in the whole study population	102
19	ROC – curve of all the parameter in VLBW	105
20	ROC – curve of all the parameter in ELBW	109
21	ROC – curve of all the parameter in LBW	111

INTRODUCTION

The transition from intrauterine to extrauterine life exposes the neonates to risk before , during or after birth. As the neonates are sensitive and fragile their mortality rates are high. Neonatal mortality constitutes two-thirds of all fatalities in the initial 12 months of life.

Preterm newborns are more exposed to a variety of complications related to the function and maturity of all other organs as their intrauterine life is shorter than the physiological limit.

Preterm births are expected to afflict 15 million babies worldwide, primarily in low- and middle-income nations (LMIC). It directly affects the survival rate, i.e one million neonatal deaths annually are contributed by preterm neonates to childhood morbidity, which is significant both in terms of perinatal, neonatal mortality and under-five mortality risk.

Preterm birth is neonates born before 37 POG. Preterm is the most common cause of adverse neonatal outcomes in terms of survival and quality of life¹. It is the top cause of perinatal and neonatal mortality and morbidity globally² Birth weight and gestational age are essential variables determining the success rate of newborns admitted to neonatal intensive care units (NICUs). But these two are not the only factors determining the outcome. The likelihood of survival also depends on physiological characteristics and other perinatal circumstances, particularly those that are connected to the severity of their disorders.³ In order to evaluate the severity of an illness and to forecast a neonate's mortality, morbidity, and prognosis in a NICU, scoring systems are necessary.

Neonates are at risk of death during this period due to the structural and functional immaturity of organs. Therefore, utmost care must be exercised for these neonates due to their fragile nature and sensitivity, as all cell are premature, sensitive, and delicate, requiring special care. Equipment's that can detect seriously ill neonate in the initial hour of life after birth aid in assessing the effectiveness of a healthcare professional and a healthcare facility. NICU performance reviews and assessments can be effectively measured by these tools. ⁴

There have been numerous distinct illness severity scores developed, such as those from Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the Clinical Risk Index for Babies (CRIB and CRI+B-II), the Agency for Healthcare Research and Quality, NICHD 2008, Vermont Oxford Network-Risk Adjustment, Score for Neonatal Acute Physiology (SNAP and SNAP-II), Score for Neonatal Acute Physiology with Perinatal Extension (SNAPPE and SNAPPE-II).⁵

SNAPPE II has been used widely in USA and Canada, the CRIB II is used in the UK and other European regions.⁶ There are limited studies from developing countries like India evaluating the predictive role of these scores in those settings.^{7–10} Additionally, very few studies have compared the CRIB II score and SNAPPE-II score in very low birth weight (VLBW) neonates.⁶

In light of this context, the current study aims to determine the predictive power of the Clinical Risk Index for Babies II(CRIB-II) and Score for Neonatal Acute Physiology with Perinatal Extension II (SNAPPE-II) risk assessment questionnaires for neonates admitted to NICUs with low birth weight or gestational age.

OBJECTIVES

- I. To determine the predictive power of the CRIB-II questionnaires in terms of risk of death among neonates with gestational age less than 34 weeks and very low birth weight admitted to the NICUs.
- II. To determine the predictive power of the SNAPPE-II questionnaires in terms of risk of death among neonates with gestational age less than 34 weeks and very low birth weight admitted to the NICUs.
- III. To assess the validity of the CRIB-II and SNAPPE-II questionnaires in low-birth-weight neonates admitted to NICU.

REVIEW OF LITERATURE

Discussed under these headings

- Epidemiology of preterm and low birth weights
 - o Burden estimate
 - o Risks, susceptibility
 - o Mortality risks
- Scoring systems
- Studies conducted in the past
- Application of predictive scores
- Performance of illness severity scores:
- Critical review of Scoring systems

Preterm Birth and LBW:

Preterm birth and LBW pose major challenges in the care of neonates. ¹¹ LBW neonates and preterm neonates terms are used interchangeably constantly but they are not same. WHO, defines prematurity as neonatal birth before 37 weeks of gestation. Preterm is further categorized into extreme preterm, early preterm (28-32 weeks) and moderate to late preterm (32-37 weeks) ¹².LBW babies are babies weighing less than 2500g at birth, and it is further divided into very LBW and severely LBW categories. ¹¹ Multiple pregnancies, undernutrition, genetics, infections, underlying comorbidities (like diabetes), persistent maternal stress, and poor socioeconomic circumstances, and the mother's lifestyle (e.g., smoking) are risk factors for preterm and LBW ¹³.

Burden Estimate:

Preterm birth, is one sole factor that has the greatest impact on neonatal outcomes that affect quality of life and survival. Globally, preterm births are leading cause of perinatal and neonatal mortality and morbidity. The WHO estimates that in 2014–2015, more than 10% of neonates (or about 15 million neonates annually) born wee preterm, and 15%–20% of infants were born with low birth weight. Low- and middle-income nations report the highest rates of neonatal death and illness, with Africa and Asia bearing the biggest share of this health burden of society. ¹⁴

In 1971, around one million deaths of children under five were reported in India, which accounted for 20% of the global total. ¹⁵ Preterm delivery was listed as the reported cause of 0.57 million (or 27.7%) of these neonate fatalities. This scenario is concerning because 23.4% of premature babies worldwide occur in India. ¹⁴ A major estimate of LBW infants is that, in the

years 2013–2014, out of almost 19 million newborns, 68.7% were weighed at birth, and of those, approximately 2.43 million births i.e 18.6% were LBW. 16 The proportion of live birth born as Very LBW has increased from 1.17% to 1.45%, as per a study data in US 17. Data from India also shows an incidence of very LBW as 1.4% to 2.08% of full live births 18,19. Despite critical care approach in the management of these neonates, their death rate is high, and constitutes to about 30% of early neonatal deaths.

Susceptibility and risks:

Compared to term neonates and neonates with normal BW ,preterm and LBW neonates have an higher risk of infections and death rate. Perinatal infection, prolongation in perinatal hospitalisation, hospital side effects of life-saving interventions, circulating maternal antibodies at low level , and developing preterm immune system constitute the main risk factors. Particularly, it is recognised that as GA and BW decrease, the immune system's immaturity increases. Neonates primarily rely on their physical barrier as their initial line of defence, followed by their innate immune response mainly more than their adaptive immunological response. Both immune defence systems are still maturing when a neonate is born. ²⁰ This developing immune system is immature in preterm neonates and those born with LBW due to several deficiencies. Survival and various morbidities of VLBW rely on a variety of perinatal variables and their clinical circumstances in addition to birth weight and gestational age. Assessment of sickness severity at admission makes it easier to identify neonates in the NICU who have a higher risk of mortality and morbidity at an early stage. This can helps in improved care of neonates and better counselling of parents.

Neonates primarily depend on physical barrier as their initial line of defence, followed by their innate primary immune response rather than adaptive immunological response. Both defence mechanisms are immature at birth ²⁰. This immune system immaturity exaggerated in neonates born preterm and LBW, due to several deficiencies. Physical barriers against pathogens include lining of mucous membranes in respiratory and gastrointestinal tracts, keratinized skin and chemical barriers contain a variety of enzymes and other substances that directly prevent microbes from attaching to bodily surfaces or that have an antibacterial effect on their own.²¹ Preterm and LBW newborns have a less formed barrier than full-term infants, which makes them more prone to ruptures and makes them more susceptible to infections. Additionally, the respiratory and gastrointestinal tracts' mucosal barriers have less flora that produces antimicrobial peptides, which makes it easier for microorganisms to access and increases the risk of infection. Multiple mechanisms initiate the innate immune response when pathogens go pass the initial barrier of protection. Due to the availability of fewer neutrophils than term and normal birthweight, this innate immune response is only partially present in preterm and LBW neonates. In addition to performing phagocytosis, neutrophils also produce oxygen radicals that aid in the intracellular death of infections. Similar to preterm and LBW newborns, there is a lower pool of monocytes available to them.²²

The activation of adaptive immune systems B-cells and T-cells, is controlled by monocytes, which are also able to present antigens, secrete cytokines or chemokines, and phagocytose. Due these, preterm and LBW infants are more likely to acquire infection early. Preterm birth is directly caused by intrauterine inflammation, which can result in rapid immune activation, cytokine production, the development of immune resistance, and impaired immune function in preterm and LBW babies. 22–24 Additionally, medical procedures performed during birth may have an impact on immunological function. For instance, maternal corticosteroid treatment to avoid neonatal respiratory illness is linked to decreased lymphocyte proliferation, decreased cytokine production, and greater infection rate. Peptides, which are soluble proteins, and immunoglobulins (Ig) encourage phagocytosis and have antimicrobial effects.

Since the fetus cannot produce many soluble proteins, maternal antibodies are mostly used to promote adaptive immunity. Around 17 weeks into pregnancy, the fetus begins to receive maternal IgG antibodies, and by 32 weeks cord blood IgG levels are comparable to maternal titters and can be up to two times higher at term birth. Because of this, the circulating maternal IgG levels in preterm newborns are low in relation to gestational age at birth. Due to this, infants are more likely to catch diseases, including ones that can be avoided with immunizations.²⁵

Mortality risk assessment:

Studies on mortality risk assessments using characteristics that could affect death rates have been conducted in many nations and neonatology units. Birthweight and gestational age were the only two reliable univariate predictors of neonatal death for a very long period. However, the correlation between these parameters and mortality prediction was not very precise. Later, more comprehensive scoring systems that aggregate physiological markers that reflect the neonate's first clinical state have been created for determining the risk of mortality. Scores are usually simple when they based on physiological changes, have fewer factors, and applied quickly; others are more extensive, consider more variables, and take longer to calculate. CRIB, CRIB II, SNAP, SNAPPE, SNAPII, and SNAPPE-II are the scoring indexes that have received the most attention and are used on neonates more frequently. Scoring systems are developed in NICU to assess the severity o and predict the mortality, morbidity, and prognosis of the neonates.

Gestational age assessment of the neonates

Ballard Score for assessment of clinical assessment of neonates:

Establishing the number of weeks of pregnancy is necessary for determining gestational age. Typically, a full-term pregnancy lasts 40 weeks. Assessment of foetal maturation is frequently the only accurate indicator of GA in these neonates because preterm neonates are commonly born to women with irregular menstruation histories or who did not get proper care prior to delivery.

With a simple and quick evaluation, a maturational assessment of neonates has been developed that is precise and applies to all neonates, including those who are born sick. Based on previous studies made by several authors on anatomical and neurological characteristics of neonates ⁴⁰ permutation and combination of different characteristics of neonates, a criteria was made up ruling out all possible difficulties encountered during the development of score. The 10 physical criteria outlined by Farr et al.⁴¹ and Dubowitz et al.⁴² were eventually integrated into six observations using a method that was developed. In addition to resting posture, angles of flexion, resistance to extension, and passive recoil, Amiel-neurologic Tison's criteria were most helpful when applied to passive as opposed to active muscle tone. Thus, six neurologic criteria and six physical criteria made up the simplified score as the end result. (Figure 1)

	0	1	2	3	4	5
Posture	⋘	€	≪⊂	岭仁	o ≱ ∑	
Square Window (wrist)	900	600	450	300	1 00	
Arm Recoil	Я 180°		100°180°	305-1000 Abr	<90.	
Popliteal Angle	.081 (80,	& €	0≟ 130°	⊕ :0°	90°	୦± <90°
Scarf Sign	P	8	8'	8	8	
Heel to Ear	8	2	oF)	2	œ.	

Physical	Maturity				,	
Skin	gelatinous red, trans- parent		superficial peeling, 8./or rash few veins	cracking pale area rare veins	parchment deep cracking no vessels	leathery cracked wrinkled
Lanugo	none	abundant	thinning	baid areas	mostly bald	
Plantar Creases	no crease	faint red marks	anterior transverse crease only	creases ant. 2/3	creases cover entire sole	
Breast	barely percept.	flat areola no bud	stippled areola I-2mm bud	raised areola 3-4mm bud	full greola 5-IOmm bud	
Ear	pinna flat, stays folded	sl. curved pinna;soft c slow recoil	pinna; soft	formed 8. firm c instant recoil	thick cartilage ear stiff	
Genitals	scrotom empty no rugae		testes descend- ing few rugae	testes down good rugae	testes pendulous deep rugae	
Genitals P	prominent clitoris & labia minora		majora & minora equally prominent	majora large minora small	clitoris 8 minora completely covered	

Score Wks. 5 26 10 28 15 30 20 32 25 34 30 36 35 38 40 40

MATURITY RATING

FIG 1: Ballard Scoring

The clinical maturity test that is described examines both physical and neurologic development equally, incorporates the components that have been found to be most helpful, and is unaffected by the existence or absence of disease. Physical changes are less noticeable during these first several weeks, but neurologic modifications between 26 and 34 weeks are prominent. Extensor tone is replaced by flexor tone, which progresses in a caudo-cephalad direction, as

part of the neurologic modifications. Additionally, the examination can evaluate functional or physiological maturity in addition to physical maturation according to the inclusion criteria. The examination can be completed in less time as the new score comprises fewer items. and is applicable to all neonates, even those in intensive care. This test is most accurate during 30 and 42 hours after birth, most likely because of its simplicity as neonates requires time to settle and adapt to life outside the womb after the delivery. (Figure 2). This imply that, once stabilised, the neonate matures more quickly outside of the uterus than inside of it.




Fig 2: Reliability of both scores related to neonatal age at examination time. Both scores are most accurate at 30 to 42 hours of life

NEW BALLARD SCORE; including extreme preterm neonates as per

Ballard et al:

The New Ballard Maturational Score was enhanced to encompass extremely preterm neonates and to increase accuracy. According to Ballard et al. ⁴³, age of gestation is the best predictor of survival and provides a precise method for assessing age of gestation in neonates with VLBW. In order to check the new tool, assess its inter-rater reliability, and define the proper postnatal ages for gestation evaluation of extreme preterm neonates and of overall neonate population, the new Ballard scoring was implemented and researched in 578 neonates. Flexibility at the wrist joint and passive flexor tone at the main joints such the knee, shoulder, and hip were observed as neurologic and physical traits that may distinguish extreme preterm neonates from term neonates. By adding a score of -1, this information enabled the expansion of four of the neuromuscular criteria. The extreme preterm neonates were observed having transparent, sticky skin without lanugo, negligible breast marks, nearly undifferentiated genitalia upon physical examination. Based on these observations, the appropriate physical items was expanded and given a score of -1. The existing score's for "plantar surface" and "ear" physical maturational criteria were both expanded. Streeter⁴⁴ and Hem⁴⁵ both shown the correlation between length of foot and gestation age. Since the gestation age determined by the last menstrual period is equal to zero, accuracy is stated as the mean difference of the gestation ages determined by the New Ballard Score and the confirmed (GLMP') methods. For extreme premature neonates, the newly expanded NBS offers a reliable and precise estimation of gestation age. At gestational ages of less than 37 weeks, the NBS exaggerates weeks of gestation by 0.3 to 0.6 weeks (2 to 4 days). Because these newborns may have endured intrauterine pressures that hastened foetal maturation, 44,45 resulting in higher maturational

scores, this discrepancy is significant statistically for validation and accuracy at GA between 32 and 37 weeks.

The Ballard score can be applied up to four days after delivery and is dependent on the neonate's maturity as of physical and neuromuscular factors (practically, in first 24 hours of life it is used). The physical components mature quickly after birth, whereas the neuromuscular components are more stable over a period.

The Ballard score is used to determine gestational age.

- Six physical and six neuromuscular signs of maturity are graded. The scores for each might be between -1 and 5. (Figure 3)
- The gestational age of the neonate is determined using the sum of the scores. The final score could range from -10 to 50..
- Low ratings are given to premature newborns. Late-born children do well academically.

Physical Maturity

The physical assessment includes following characteristics examination

- **Skin texture:** Skin is sticky, translucent, or peeling.
- Lanugo: Soft downy hair on a neonates body; usually absent in neonates born early but not in babies born late.
- **Plantar creases:** Lines on the soles of the foot. They can either be completely absent or completely covered..
- **Breast**: The areola (the darkened region surrounding each nipple) characteristic and breast tissue size are measured.

- Ears And Eyes Checking whether the eyelids are open or fused shut (more likely in a premature baby). Additionally noted are the quantity of cartilage and the ear tissue's stiffness.
- Male Genitalia. To look for testes and that the scrotum is both smooth and wrinkled.
- **Female Genital**ia. It is noted how the clitoris and the labia look and measure.

Neuromuscular Assessment

The neuromuscular assessment includes characteristics as follows for examination

- **Posture:** Position of ease of the neonates all 4 limbs at rest. Reflects muscle tone
- **Square window**: Ease of flex neonates hand in the direction of the wrist. Assess flexibility of wrist and resistance to extensor stretching.
- **Arm recoil.** How quickly the neonates' arms can flex back into place. Assess passive flexor tone of biceps followed by brief extension of upper extremity.
- The popliteal angle the neonates' knees' ability to bend and straighten. Assess knee passive extensor muscles tone and resistance to extension
- Scarf sign. how much room there is between the elbows and the neonate's chest. Assess tone of flexors around shoulder gridle passively.
- **Heel to ear**: How close the neonates heel may come to their ear. Assess neonates hip flexor muscle passive tone.

	-1	0	t	2	3	4	5
Posture		₩	E	\ll	实	ŒĹ,	
Square Window (wrist)	>90*	90*	60.	150) 30°	, 0*	
Arm Recoil		A 1800	140*-180*	20 € 110• · 140*	90-110*	\$\\\	
Popliteat Angle	8	گا	A 140°	D 150.	D)	g.,	∞≤,,,
Scarf Sign	-8-	-8	-8	-8	-8	-8	
Heel to Ear	(m)	É	É	Éto	æ}	É	

ysical Ma	turity							Maturity	y Rating
Skin	sticky triable transparent	gelatinous red, translucent	smooth pink, visible veins	superficial peeling &/or rash. few years	cracking pale areas rare veins	parchment deep cracking no yeasels	leathery cracked wrinkled	score - to	weeks 20
				Tew Years	bald	mostly		-6	22
Lanugo	none	sparse	abundant	thinning	areas	baid		0	24
Plantar	heel-toe	> 50mm	faint	anterior	creases	creases		5	26
Surface	40~50 mm: -1 <40 mm: -2	crease	red marks	transverse crease only	ant. 2/3	entire sole		10	28
_		barely	tiat areola	stippled areola	raised	full areola 5-10mm		15	30
Breast	imperceptible	perceptible	no bud	1-2mm bud	3-4mm bod	bud		20	35
	lids tused	lids open pinna flat	st. curved pinna; soft;	well-curved pinna;	formed Stirm	thick cartilage		25	34
Eye/Ear	loceely:-1 tightly:-2	stays folded	slow recoil	soft but ready recoil	instant recoil	ear soft		30	36
	scrotum tlat.	acrotum	testes in upper canal	testes descending	testes down	testes pendulous		35	38
Genitals male	smooth	taint rugae	rare rugae	few rugae	good rugae	deep rugae		40	40
	clitoris	prominent clitoria	prominent clitoris	majora & minora	majora large	majora cover		45	42
Genitals	labia flat	smail labia minora	enlarging minora	equally	minora small	clitoris & minora		50	44

Fig 3: The New Ballard Score

SCORING SYSTEMS FOR NEONATES

CRIB

The Clinical Risk Index for Babies (CRIB) score was developed to forecast the death of neonates who were lesser than 32 weeks gestational age at birth. Neonates who were hospitalised to four tertiary neonatal facilities in the UK between 1988 and 1990 were the source of the data.²⁷ The cohort included 812 babies with VLBW, and 25% of them expired. The six variables that were most effective at predicting death were determined by the authors using logistic regression. Six factors make up the score, including a birth and clinical features components. It's important to remember that CRIB encompasses congenital problems that are not fatal and fall into the general categories of (1) not present, (2) not immediately life-threatening and (3) immediately life-threatening. This include comorbidity adjustment in the score, to put it another way. The CRIB clarifies population underlying risk in a way that systems using solely physiological indicators do not. This manoeuvre aids in highlighting variations in results received through the score (For instance, individuals who have cardiac problems are at a different risk than those who do not, depending on their infant's oxygen needs or blood gas readings).

Because it takes less time to complete, includes birth anomalies, and is still more accurate than birth weight alone, the CRIB may have some advantages over other early scores. When determining the severity of the sickness, GA of less than 31 weeks neonates and those with birth weights under 1,500 g are recognised as mortality indicator in neonates with LBW.

CRIB - variables

BW
Gestation
Congenital malformation
Maximum base deficit in first 12 h
Minimum appropriate FiO2 in first 12 h
Maximum appropriate FiO2 in first 12 h


CRIB II

Parry et al¹⁴ updated the CRIB by publishing the CRIB II in 2003. Data from a cohort study in UK of neonates born during 1998 and 1999 was acquired²⁸. The authors hypothesised that prenatal steroids and surfactant were the norm in the original sample, potentially increasing results and modifying risk of death. The most recent CRIB II is on information gathered in the initial hour of life and does not account for the likelihood of birth abnormalities. Despite the lack of comorbidity correction .It was discovered that CRIB II had better distinction than the initial CRIB score. To assess initial mortality risk, factors like BW, gestation age, temperature, base excess, and sex are taken into consideration.¹⁰

CRIB II varied from 0 to 27, (Figure 4), lower scores yielding better outcome of neonate and a score of one yielding the most favourable outcomes. The maximum score for BW and GA is 15, seen in male neonate who born at 22 weeks and birthweight of 501g.

CRIB II- Scoring system variables

Parameters	
1. BW	
2. POG	
3. Sex	
4. Temperature	
5. Base deficit in ABG in first 12 hours	



Clinical risk index for babies II (CRIB II) score

Fig 4: CRIB II- Scoring system

The range of the overall CRIB II score is 0 to 27. The scores have also been divided into the following four levels.:

Level 1 - O to 5.

Level 2 - 6 to 10.

Level 3 - 11 to 15.

Level 4 - Above 15.

The prognosis becomes worse as the score increases, with levels 3 and 4 having the poorest prognosis. According to earlier research, the ideal cutoff point for receiver operating characteristic is at 4.

SNAP & SNAPPE

Richardson et al. released SNAP for the first time in 1993. ²⁹ The Acute Physiology and Chronic Health Evaluation in critically sick people and the Physiology Stability Index served as models for the design of the SNAP. The SNAP components use the least favourable physiologic measurement among a number that takes place in a span of the 24 hours of admission (e.g., blood gas ,pH, MAP). Three Boston NICUs used a cohort of infants born in 1989 and 1990 to create the score. For neonates of all birthweights, SNAP comprises 26 clinical and vital variables, and for assessment it takes 5 to 15 minutes per patient to complete (depending on patient complexity). Strong accuracy was observed in the score's ability to predict neonatal in-hospital death. Birthweight, a 5-minute APGAR score, and SGA (5th percentile) are added to the physiologic variables of the SNAPPE, which also includes physiologic variable data from SNAP.³⁰ Compared to birthweight alone, SNAP and SNAP-PE clearly offered benefits and superiority. Their primary flaw was intensive the data collection process.

SNAP- Scoring system variables

- BP
- RR

HR

- Temperature
- PaO2
- PaO2/FiO2 ratio
- PaCO2
- OI

•	PCV
•	WBC
•	ITR
•	ANC
•	Platelet count
•	BUN
•	Creatinine
•	UO
•	Indirect bilirubin.
•	Direct bilirubin.
•	Na ⁺
•	K^+
•	Ca ²⁺ (ionised)
•	Ca ²⁺ (total)
•	Glucose
•	Serum bicarbonate
•	Serum pH
•	Seizure
•	Apnea
•	Stool guaiac

SNAP PE- Scoring system variables

SNAP score plus

- BW.
- APGAR score,7 at 5 min
- SGA

SNAP II SNAPPE II

The SNAP and SNAP-PE were both updated by Richardson et al. in 2001. Their revised scores, SNAP II and SNAP-PE II, attempted to provide a more efficient strategy. ³¹ To create and validate their scores, the authors used a sizable group of newborns born in 1996 and 1997 in New England, California, and Canada. The SNAP's components were edited down to 6 elements (MBP, lowest recorded temperature, PaO2 / FiO2 ratio, serum pH, multiple convulsions, and UO), which made it easier for data abstractors to score tests in 4 minutes or less. Additionally, data were gathered 12 hours after admission rather than 24 hours later to minimize the initial treatment impact on scoring. Similar to the initial SNAP score, SNAP II was also extended to create the SNAPPE- II by including the perinatal extension factors. The improved SNAPPE II scores were accurate at predicting neonate morality and mortality in both high- and low-risk populations.

SNAP II Scoring system variables ³⁰

- MBP
- Lowest temperature.
- paO2/ FiO2 ratio.
- Serum pH
- Multiple seizures
- UO

SNAPE PEII- Scoring system variables

SNAP II score plus:

• BW.	
• Apgar at 5 min.	
Congenital malformation.	
• SGA.	

SNAPPE II - Scoring variable with scores

Variables	Measures	Score
Lowest MBP	>29mmHg	0
	<29mmHg	9
Lowest temperature	>35.6C	0
	35-35.5C	8
	<35C	15
PaO2/FiO2	>2.49	0
	1.0-2.49	5
	0.3-0.99	16
	<0.3	28
Lowest Ph	>7.19	0
	7.10-7.19	7
	<7.10	16

Seizures	None	0
	Yes	5
	>0.9ml/kg/h	0
Urine Output	0.1-0.9ml/kg/h	5
	<0.1ml/kg/h	18
	>999g	0
Birth weight	750 – 999g	10
	<750g	17
Small for gestational age	<3 rd percentile	0
	<3 rd percentile	12
APGAR score at 5 minutes	>7	0
	<7	18

ARTERIAL BLOOD GAS ANALYSIS.

The norm for determining the neonate's oxygenation, ventilation, and acid-base status is arterial blood gas monitoring. Blood gas analysis is a used as diagnostic tool for assessing acid base features and partial pressure of gases. An oxygen (PaCO2) and carbon dioxide partial pressure (PaCO2) analysis is performed on newborns. Information on the status of oxygenation and ventilation is provided by PaO2 and PaCO2.

Acid-base status, hypoventilation (slow or shallow breathing), and hyperventilation (quick or deep breathing) have impact on PaCO2. Pulse oximetry and end-tidal CO₂ monitoring are non-invasive evaluation of oxygenation and ventilation, ABG analysis is the gold standard method.⁴⁶

Oxygenation

Central cyanosis serves as the primary indication for the administration of oxygen. Acrocyanosis without central cyanosis does not warrant the delivery of oxygen. Instead of flow per minute, oxygen delivery should be dependent on a percentage of inspired oxygen (FiO2). In contrast to hyperoxia, which can harm preterm neonates' eyes, hypoxia can cause mortality and brain damage. Based on arterial oxygen tension, target oxygen is adjusted (PaO2) Arterial oxygen tension in children should be between 70 and 100 mm Hg, and between 50 and 70 mm Hg in term newborns. False hypoxia may be identified in individuals who have polycythemia, processing issues, venous blood, or who are deliriously ill. PaO2 monitoring has been proven to have flaws despite being widely used. When blood gas samples are taken with indwelling catheters in a quiet environment, the results are most accurate..

For collection of Samples: Radial or umbilical arteries are the best options for neonatal artery sampling. Before piercing the radial artery, "Allen Test" should be performed to verify collateral blood flow in the ulnar artery. A sample from an umbilical artery catheter (UAC), should ensure that blood is flowing freely and remove three to four times the volume of dead space. Indwelling arterial lines should only be implanted if 24-hour ABG estimation facilities are available since they represent a serious risk of infection.

A "blood gas analysis" usually can be performed by collection of blood either from artery, vein or capillary but arterial sampling explicities other samples in circulation.

Arterialized capillary samples are comparable to arterial blood. It is necessary to collect a capillary sample (100–150 microliters) from the warmed heel and to wait for the capillary to fill up with blood at the tissue site. Do not squeeze or draw the initial drop of blood. To combine the anticoagulant and the blood, rotate the capillary in your hand. Make that the capillary is free of air bubbles. While venous blood is ineffective for determining pH, pCO2, and pO2, it is effective in determining HCO3.. A tourniquet should not be used, the artery should not be squeezed, and the sample should not be extracted with the blood flowing toward the heart.

Comparison of Blood Gas Analysis at different sites

	Arterial	Capillary	Venous	
рН	Same		Lower	
pO2	Higher		Lower	
pCO2	Lower		Higher	
нсоз	Same		Same	
Recommendation	Good	Fair	Bad	

Precautions for collection of blood sample

- (1) Heparin reduces pH as it is acidic. Use heplock solution or a weaker form of heparin (1000 units per ml as opposed to 5000 units per ml).
- (2) Use a tiny amount of heparinized saline to lubricate the plunger and syringe alone. Dissolved oxygen in heparinized saline may raise pO2 if volume is greater.
- (3) Prevent air bubbles and allow the syringe to fill naturally.
- (4) Glass syringes are preferable since plastic syringes allow air to pass through them.

To lessen the chance of inaccurate results, the sample should be processed instantly. Arterial blood should be collected, kept on slush of ice, and then promptly analysed. Being a biological medium cells in blood use oxygen and release CO2 as byproducts. Initial pO2 determines how much pO2 drops. The latter could experience a big drop if it is quite high. Before inserting the sample into the machine, it should be agitated and homogenised.. Blood gas samples are frequently analysed using automated devices that produce results in 10 to 15 minutes.

Automated blood gas analysers measure particular arterial blood gas sample constituents both directly and inferentially.

Normal Neonatal ABG values

pH 7.35 – 7.45mmHg

pCO2 35 - 45 mm Hg

pO2 50 - 70 mm Hg

HCO3 20 - 24 mEq/L

 $BE \pm 5$.

Target blood gas values of a neonate

paO2 45-65 50-70
pCO2 40-50 40-60
pH >7.25 >7.25

Base excess (BE): Neonates have a buffer base (BB) concentration of 48–49 mmol/L total. HCO3 accounts for 50% of this, followed by haemoglobin buffers at 25%, and protein, sulphate, and phosphate buffers at 25%. A BE score of less than five is regarded as normal. Abnormal pH with BE> -5 (base deficit >5) with imbalance needs intervention. Basic supportive care and specific therapies intended to address the underlying cause are used to treat neonatal metabolic acidosis. Metabolic acidosis caused on by asphyxia or inadequate tissue perfusion is typically corrected by treating hypothermia, hypovolemia, (anaemia, hypoxia, and electrolyte abnormalities). If sepsis is suspected, antibiotics should be administered. A significant number of infants need ventilator support. 46

Interpretation

It is optimal to approach the arterial blood gases methodically, identifying the degree or severity of aberrations, their duration either acute vs chronic, and if the underlying problem is respiratory or metabolic in nature.

The first step is to check the pH to see whether there is acidemia (pH 7.35) or alkalemia (pH > 7.45). Normal pH is between 7.3 and 7.45, use a cut off value of 7.40. In other words, a pH of 7.37 is considered acidosis, whereas a alkalemia is when pH of 7.42. To ascertain the components of respiratory and metabolic analyse the ABG's, PaCO2 and HCO3 data. The paCO2 indicates a respiratory or metabolic acidosis or alkalosis is the main cause of the acidosis or alkalemia. Respiratory alkalosis is indicated by PaCO2 40 and pH > 7.4, whereas respiratory acidosis is indicated by PaCO2 > 40 and pH > 7.4. (however this is frequently caused by anxiety-induced hyperventilation or compensatory hypoxia).

Next, determine whether a number (PaCO2 or HCO3) that deviates from pH is indicative of compensatory acidosis or alkalosis. Once again check the PaO2 for any abnormalities in oxygenation.

Oxvgen Saturation:

The normal ranges for arterial oxygen tension in children are 70-100 mm Hg and 50-70 mm Hg in term infants. Pseudo hypoxia may be detected in cases of polycythemia, processing delays, venous blood, or in patients who are feverish. Despite being widely utilised, paO2 monitoring has been found to have shortcomings. When blood gas samples from indwelling catheters are taken under peaceful, resting conditions, the validity of the values is maximised.

Hemoglobin saturation is calculated as the ratio of the amount of oxygen bound to haemoglobin to the maximum amount of oxygen that can be bound to haemoglobin. Pulse oximetry is useful for observing oxygenation trends. Compared to TcPO2 monitors, this technology is less complicated and does not require the same level of user expertise or calibration. It gauges peripheral haemoglobin O2 saturation (SaO2). Sometimes, movement artefacts might severely restrict the use of these techniques. High-intensity light, >50% foetal Hb, and other conditions can also cause saturation measurement errors. Since pulse oximetry does not measure paO2, it is comparatively insensitive to the presence of hyperoxemia. This is especially crucial for little preterm babies. The ideal haemoglobin saturation level for acute lung disease is 88 to 93% as determined by the pulse oximeter. 95–98% saturation is typical. If saturation falls below 75%, clinical cyanosis becomes obvious. Hemoglobin A is 75% saturated at paO2 of 40 mmHg, 50% saturated at paO2 of 27 mmHg (P50), and 90% saturated at paO2 of 60 mmHg. ⁴⁶ (Figures 5, 6)

Oxygen Dissociation Curve - Fetal Haemoglobin




FIG:5: Oxygen Dissociation Curve – Fetal Hemoglobin v/s Adult Hemoglobin




Figure 6: Oxygen Dissociation Curve of Neonate

Effect of temperature and pH on Oxygen Dissociation Curve

The oxygen dissociation curve is a sigmoid shape curve which plateaus at pO2 > 70 mm Hg. A patient with a very high paO2 usually has saturation of 97–99%. (Figure II). Changes in the haemoglobin type, pH, temperature and 2,3-diphosphoglycerate concentrations all have an impact on where the oxy-hemoglobin dissociation curve is located (2,3-DPG). Fetal haemoglobin has stronger affinity for oxygen binding than adult haemoglobin, which causes it to push the curve to the left. The paO2 at which haemoglobin is 50% saturated (P50) decreases as a result. The foetus benefits from this change because it favours O_2 utilization at the placenta's low O_2 tensions. During the initial few months of life, the oxy-hemoglobin dissociation curve shift to the right, reaching adult values by 4 and 6 months of age. (Figure 7)




Figure 7: Effect of temperature and pH on Oxygen Dissociation Curve

APGAR for Neonatal Resuscitation

Dr Virginia Apgar created a scoring system in 1952 as a quick way to determine the neonates clinical condition at one minute of age and the need for immediate intervention to establish breathing. A scoring system gave newborns a consistent evaluation following delivery. The Apgar score (Figure 8) is made from of 5 parameters: (1) color; (2) heart rate; (3) reflexes; (4) muscle tone; and (5) respiration. A score of 0, 1, or 2 is assigned to each of these factors. The Apgar score measures the clinical signs of neonatal depression, including appearance, heart rate, a reflex response to stimuli, tone, and respirations.

THE APGAR SCORE				
	Sign	0 POINTS	1 POINTS	2 POINTS
A	Appearance	blue or pale	blue extremities pink body	body & extremities pink, no cyanosis
P	Pulse	absent	<100 beats per minute	>100 beats per minute
G	Grimace	no response to stimulation, floppy	grimace on suction or aggressive stimulation	cry on stimulation
A	Activity	none	some flexion of arms and legs	active flexion against resistance
R	Respirations	absent	weak, irregular and slow	strong crying

FIG 8 : APGAR score with parameters and scores

At 1 and 5 minutes after birth, the score is recorded for every neonate. Scores for babies with scores between 7, are provided every five minutes from then on until twenty minutes. The Apgar score is a recognised and practical way to report on the neonate baby's condition just after birth and their reaction to resuscitation. According to the 2011 Neonatal Resuscitation Program recommendations, stopping resuscitative measures "may be reasonable if you can determine that no heart rhythm has been observed for at least 10 minutes."

According to the Neonatal Encephalopathy and Neurologic Outcome report, a APGAR score of 7 to 10 is regarded as positive at 5 minutes of life, a score of 4 to 6 as abnormal, and a score of 0 to 3 as low in term and near term neonates. A non-specific symptom that "may be

one of the early indicators of encephalopathy" is Apgar score of 0 to 3 at 5 minutes or more of life. ⁵⁰ According to the definition of asphyxia, it is the significant disruption of gas exchange that, if left untreated, results in progressive hypoxemia, hypercapnia, and significant metabolic acidosis. A useful indicator of a neonate response to resuscitation is the APGAR score at 5 minutes more specifically, ia change in the score between 1 and 5 minutes of life.

TEMPERATURE

The infant's mortality and morbidity may be severely affected by hypothermia and hyperthermia. The onset of haemorrhagic processes is brought on by hypothermia, which also alters glucose homeostasis and increases oxygen consumption. Dehydration, hypernatremia, and eventual death can all result from hyperthermia, as potentially cause cerebral damage. Neonatal should be dried and placed under radiant heat as soon as possible after delivery.

Assessment of temperature: Skin temperature

A thermistor probe is softly taped to the skin to record it. The skin on the trunk has a greater central skin temperature than the skin on the rest of the body. The skin's core temperature is more constant. In term neonates , the typical abdomen temperature ranges from 36 ± 0.5 C. Due to insufficient subcutaneous tissue, the skin temperatures of premature newborns range from 36.6 ± 0.6 C , which is near to the core temperature. Infants who are in shock or who are collapsing will have a differential in skin temperature between their centre and periphery. Suspect sepsis if the difference is more than 1.5 C. Abnormal temperature readings are the result of attaching skin probes to skin that has been burned or injured.

Definition of temperature variations in neonates

Hyperthermia when temperature is > 37.5 °C.

Normal temperature from 37 ± 0.5 °C.

Cold stress is temperature 36.2±0.2 °C.

Moderate hypothermia 34.2±2.2°C.

Severe hypothermia - < 32 °C.

SHOCK

Shock is a pathophysiologic state of inadequate tissue perfusion. This effects is reversible initially, but prolonged hypoperfusion and tissue hypoxia can disrupt critical biochemical processes, which if not addressed, result in cell death, end-organ failure, and, possibly, death. In neonatal critical care units, perfusion disorders in neonates are frequently seen. The majority of the existing assessment techniques are based on clinical indicators.

Capillary refilling time, urine output, heart rate, peripheral colour, base excess in ABG, lactate concentration, and blood pressure are examples of commonly recommended symptoms. Each measurement's permissible limits are embedded in practise, but they all take end-organ perfusion into account ⁵¹

HYPOTENSION:

According to reports, 16 to 52% ^{51,52} of premature neonate's experience hypotension. Because there is a chance of negative short- and long-term prognoses, it is crucial to identify and treat hypotension in preterm newborns. Preterm infants' blood pressure can be tested noninvasively and invasively, using intra-arterial catheters. The standard of care is invasive blood pressure measurement. The pressure required to enable appropriate organ perfusion should be used to define normal BP. Depending on GA, birth weight, and postnatal age, the typical values will vary. 73% of units across the 38 nations studies the diagnosis of hypotension in neonates with extraordinarily low gestational ages was made when the mean blood pressure recorded was less than the gestational age as the criterion. All of these have a minimal impact on mean blood pressure, making it dependable even in the context of a damped trace. It reflects the perfusion pressure and is derived from the systolic and diastolic pressures.⁵²

Cunningham et al ⁵³ has analysed on a large cohort of patients during initial seven days of life in VLBW neonates excluding infants on inotropic support and IVH. He said hypotension is less than the 10th centile for BW (Figure 9) and postnatal age. Hypotension affects perfusion to all organs leading to multiorgan dysfunction mainly affecting cerebral blood flow .




Fig 9: Mean Arterial Pressure at different Birthweight – 10th percentile



Fig 10: NIBP measured in neonate

British Association of Perinatal Medicine experts recommended and proposed a guidelines on mean blood pressure (MBP) implementation in management of respiratory distress syndrome neonates as the value of mean blood pressure less than the gestational age neonates 31 weeks gestation were reported to have serious haemorrhage, ischemic brain lesions, or die within 48 hours if their mean blood pressure was 30 mm Hg for 1 hour. A thorough evaluation of perfusion provides more useful information than merely using mean blood pressure. More often, measures of systolic and diastolic blood pressure that reflect cardiac function and systemic vascular resistance should be utilised to guide therapy.

URINE OUTPUT

UO demonstrated good in-hospital mortality prediction performance. Patients with lower UO had higher SNAPPE-II scores and greater perinatal asphyxia at NICU admission. Additionally, these patients exhibited higher levels of metabolic issues (acidosis and hyperkalaemia), which are risk factors for AKI (perinatal asphyxia). These characteristics imply that renal impairment was essentially present in patients with decreased UO. In individuals with limited UO, mechanical ventilation lasted longer. Because larger values indicate death in LBW neonates, LBW was a protective factor against lower UO. UO was a standalone mortality predictor in the multivariate study.

Other Scoring System

National Institute of Child Health And Human Development (NICHHD)

Using data from 1823 children born between 1987 and 1989, weighing 501–1500 g³⁴, who were admitted to seven United States neonatal intensive care, the NICHHD score was developed. The variables were chosen through the use of logistic regression, and another 1780 infants were utilised for validation. Since its creation, it has not been extensively utilised.

NICHHD- Scoring system variables

BW
Apgar score at 1 min
Race
SGA
Sex

Berlin Score

With 396 VLBW development neonates ,176 VLBW neonates validated between 1988 and 1991, this German score was created using logistic regression techniques. ³⁰ Its incorporation of several arbitrary factors³⁵ causes problems. Because of the addition of these data points, it can no longer be used to compare units objectively.

Berlin Score- Scoring system variables

Birth weight
Respiratory Distress Syndrome grading
Artificial ventilation
APGAR score at 5 min
Base excess at admission
Dase excess at admission

Neonatal Mortality Prognosis Index (NMPI)

To determine the predictive markers collected up to 12 hours after admission from 336 Mexican neonates in 1993³⁶, this score was created using logistic regression. A second cohort of 300 neonates was used to validate the model. It has not been utilised extensively.

NMPI- Scoring system variables ³⁶

BW
GA
Cardiac arrest
PaO ₂ / FiO ₂ ratio
Major congenital malformations
Sepsis
Base excess

Vermont Oxford Network-Risk Adjustment and Revalidation of

SNAP II/SNAP-PE II

The Vermont Oxford Network compares results among its 500 centres using a unique method of risk adjustment called VON-RA. Zupancic et al.³⁷ Initial study that introduced the VON-RA was released in 2007. This study was based on information gathered in 2002, when 58 participating centres attempted SNAP II and SNAP-PE II must be revalidated. The researchers also intended to assess the VON-RA's performance in relation to these scores and ascertain the relative impact of birth abnormalities on the VON-RA performance. Importantly, this research discovered that the performance of the SNAP-PE II score was greatly enhanced by the inclusion of birth abnormalities. The research also revealed similarly results to the SNAP-PE II plus birth defects.

Application of predictive scores:

For comparison of performances among varied neonatal intensive care units, it is widely accepted that outcomes results must be appropriately adjusted for case mix variations (risk adjustment). The acceptance of "good" results from a unit that tends to solely serve patients with favourable prognoses. Conversely, those who care for patients with poor prognoses should anticipate more "bad" results. In these scenarios, The neonatal morbidity at the time of its arrival into the charge of the unit should be assessed. In order to compare healthcare professionals and units, illness severity scores are now widely recognised as crucial instruments. The rates of medication use, blood transfusions, and other outcomes have all been examined using illness severity scores. The other situations where predictive scores find their application are determining the trends in results over time and giving prognostic information to individual children. 5

Performance Of Illness Severity Scores:

The score had superior discriminatory capacity than birth weight alone (Az = 0.78) in the original study that led to the establishment of CRIB (area under the ROC curve: Az = 0.90). Although CRIB was a better predictor of hospital mortality than BW alone, its relation with morbidity was undefined clearly. The appropriateness of CRIB with contemporary data was reconsidered, as score might be poorly calibrated to mortality following NICU, as BW and GA alone were poor predictors than this score. CRIB included data up to 12 hours after admission, introducing a treatment bias. When compared to other more complex scores, such as SNAP and SNAP-PE, the CRIB's data acquisition is significantly more simple, with each neonates calculation taking only five minutes as contrasted to 20 to 30 minutes.⁵

The recalibrated and streamlined scoring system offered by CRIB II does deal with any potential issues that could arise from using FiO2 and data collected up to 12 hours after admission. The findings of Patrick et al. regarding decreasing hospital mortality since 1988 were in accordance with those of other studies³⁰. This decline might be explained by improved clinical judgement, the introduction of surfactant therapy in the late 1980s, and the rise in prenatal steroid use in the early 1990s. The creators of CRIB-2 recommended more research to determine the long-term effects of greater clinical abilities, increased uptake of efficient treatments, and improved service organisation on health outcomes. Before assessing declining mortality as a health gain, they also advocated for routine evaluation of the long-term health of neonatal intensive care survivors.

In Richardson's comparison, SNAP-PE was even more accurate for predicting death than birthweight alone (Az 0.87 v 0.77). (Az 0.93). ³⁰ Due to the quantity and complexity of the elements, SNAP proved problematic to use as a first-generation neonatal illness severity index score.

The authors of SNAPPE II have outlined a number of justifications for their conclusions, some of which are listed below.³¹ GA was chosen over BW in perinatal extension as it was more physiological and acceptable to the population norm. That decision was made due to limitations on the gestational age's accuracy and availability. Pao2 / Fio2 was chosen over other alveolar ratio with arterial oxygen or difference as it require any additional parameters like mean airway pressure or concurrent carbon dioxide tension. They made an effort to get rid off with the UO because it calls for risky bedside calculations and is susceptible to inaccurate measurement. Even among infants with very low birth weights, it continued to be consistently highly predictive, and it is a significant predictor in babies with greater birthweights. The data collecting window was lowered from the period of 24 hours to 12 hours. Thus, the impacts of treatment bias are lessened. Even if it was possible, reducing the data collecting window to less than 12 hours might have led to deteriorating data quality and decreased predictive power. In SNAPPE- II, the physiological parameters were differentiated from the additional risk that was posed by birth weight, SGA, and Apgar scores. This was done in order to give academics and medical professionals a mechanism to account for mortality risk factor against birthweight ranges while still comparing basic physiological abnormalities within constrained birth weight strata. In contrast to the CRIB, ratings in adult and paediatric intensive care units distinguish physiologic variations from other risk factors. The scientists also believed that as intensive care advances, the relative proportions of illness severity and birth weight may change over time with reference to mortality.

Because the physiologic variables for SNAP-II were calculated from mortality risk, they were extremely wide. In the original SNAP, they did not retain a wide variety of sublethal physiologic derangements. They propose that SNAP might still be a more effective tool for research on the treatment of individuals who are just mildly unwell, such as neonatal triage. The SNAPPE - II score at admission describes the risk of neonatal mortality during the first 12 hours. It is not intended to be used as a sequential score over a period of time. Richardson et al. optimised

the calibration separately after first elaborating the SNAP- II and SNAPPE -II scores. This made it possible for the two scores to continue to be simple additive sums while also allowing us to include sophisticated higher order and interacting terms to improve the fit.

Critical Review Of Scoring Systems.

A cut-off of 27.5 for SNAPPE II was reported, with 84% sensitivity and 79% specificity, and reported accuracy of 0.887 (CI 95%:0.847-0.927) (P0.05). Dalili et al. evaluated CRIB II and SNAP PE II for predicting mortality in preterm (32 weeks) or LBW (1500 g) admitted to NICU in Iran. The cut off of 27.5 to 29.5 and Youden's index was 0.64. The SNAPPE-II found that at a cut-off point of 27, prognostic sensitivity of 84.44% and specificity 79.05%. Additionally, these comparable results were 82.22% (CI 95%: 82.222 - 82.223) and 81.42% (CI 95%: 81.422 - 8.423) at the cut-off point of 29.5. According to same study, the CRIB II method has a cut-off point of 8.5 with sensitivity and specificity of 74.4% and 78.65%, respectively. For a one-unit rise in SNAPPE-II and a one level in CRIB-II, respectively, the chances of neonatal mortality increased by 1.05 (CI 95%: 1.02-1.1102) and 2.696 (CI 95%: 1.59-4.72) respectively. These conclusions were reached after taking into account factors like IVH, head circumference, length of hospital stay, weight, height, and height.

Timothy et al assessed SNAPPE II as a predictor of neonatal mortality in a general hospital's NICU, Indonesia reported a strong association between SNAPPE II and mortality and recommended a cut-off of 51. This study also demonstrated great calibration using the Hosmer-Lemeshow goodness-of-fit and excellent discrimination (AUC 0.933, 95% CI- 0.843-1). A higher cut-off indicates that the centre's neonates have higher survival rates. Patrick et al evaluation .'s of 10 distinct risk adjustment scores for neonates mortality highlighted the necessity for risk adjustment to alter as clinical population demands and conditions change and the need for additional research for extrapolation people in other developed countries and to developing country population settings.⁴

The cut-off score point for neonatal mortality prediction was 38, with a sensitivity of 84.4% and specificity of 91%, according to Muktan et al prospective observational study carried

out in Nepal to evaluate the reliability of the SNAPPE- II score as a predictor of neonatal mortality and length of stay in NICU.⁹ The babies who passed away had significantly higher median (IQR) SNAPPE II scores [57 (42-64) vs. 22(14-32), P 0.001] than the surviving children. The area under the curve (AUC) for the ROC curve was 0.917 [95% CI 0.854-0.980]. The most reliable method for predicting overall mortality was the SNAPPE II cut-off score of 38. The sensitivity, specificity, positive predictive value, and negative predictive value of the overall mortality estimate are 84.4, 91, 66.7, and 96.5%, respectively, for estimating overall mortality.

The CRIB II score was found to be a reliable tool for initial risk assessment in LBW in a prospective study by Eldin from Egypt, with a cutoff point of 11 being highly sensitive (94.9%) and reasonably good specificity (82.4%)7. Eldin's study also indicates that mortality increased steadily as CRIB II score levels increased; mortality was (0%), (4.8%), (68.3%) and (100%) in level I, level II, level III, and level IV of CRIB II, respectively. For CRIB II, GA and BW, the areas under the curve (AUC) were 0.968 (95% CI=0.940-0.996), 0.900 (95% CI=0.844-0.957), and 0.834 (95% CI=0.753-0.914), respectively. Additionally, ROC curve analysis showed that the cut-off points of 11 for CRIB II score, 28 for gestational age, and 1100 for birthweight had the best sensitivity and specificity for predicting death. The CRIB II score (86.7%) was shown to have the highest accuracy (the percentage of genuine outcomes, including true positives and true negatives), followed by gestational age (81.4%) and birthweight (72.5%).

SNAP PE-II and CRIB-II illness severity scores were used in another prospective multicentric study in the Indian population by Vardhelli et al. to predict neonatal mortality and morbidities in 32 weeks POG. Both scores had better predictive ability in hospital mortality, namely CRIB-II (AUC 0.795) and SNAPPE II (AUC: 0.78).³⁹ CRIB II and SNAPPE II had comparable AUCs for mortality predictivity, with CRIB-II's AUC .of 0.79 (95% confidence interval (CI): 0.73-0.86) and SNAPPE-AUC II's of 0.78 (95% CI: 0.69-0.86) showing no statistically significant difference between them (difference: 0.016, 95% CI: 0.09 to 0.06, P-

value: 0.6) The discriminatory power of the two scoring systems was comparable (SNAPPE-II: HL 2 = 2.157, 6 degrees of freedom (d.f.); p = 0.905; CRIB-II HL 2 = 6.579, 8 d.f.; p = 0.583). With AUCs of 0.83 vs 0.70 and 0.85 vs 0.74, respectively, CRIB-II beat SNAPPE-II in its ability to predict important morbidities and their combined unfavourable result. AUC was similar to CRIB II in terms of mortality prediction (0.78 vs 0.79), however SNAPPE-II showed higher accuracy (73.7% vs. 60%). The mortality and morbidities increased along with the rise in SNAPPE-II and CRIB-II scores, with the exception of SNAPPE-ability II's to predict Retinopathy of Prematurity (ROP) requiring treatment.

According to a Harsha and Archana, a SNAPPE-II score of 37 or above was linked to a greater mortality rate. ⁸ In term neonates, the mean SNAPPE-II score was 24.1 (15) for children who survived and 52.8 (15) for children who died, but in preterm neonate, the scores were 14.87 (13), 31.7 (16), and 14.87 (13), respectively, for children who survived and died. Regardless of gestational age, SNAPPE-II demonstrated a high association with the result in terms of mortality. In this study, increased mortality was linked to SNAPPE-II scores of 37 and above.

Gagliardi *et al* a VLBW neonates in 12 NICUs of local network study was conducted in Italy between 1999 and 2001, it assessed the effectiveness of CRIB, CRIB-II, and SNAPPE-II to evaluate in-hospital mortality. CRIB and CRIB-II showed greater variation than SNAPPE-II. (AUC 0.90 and 0.91 compared to 0.84) They suggested that a few variables needed for the SNAPPE-II computation may not have been of high quality, such as urine production in VLBW neonates. None of the ratings offered a reliable prediction of the likelihood of death because multiple additional variables that were closely connected with survival in several logistic regression models were included in addition to the scores. Antenatal steroid treatment, caesarean section, singleton delivery, APGAR score of greater than seven at 5 minutes, lack of SGA, absence of any congenital abnormality were tended to be significantly correlated to longer survival among VLBW neonate.

Dorling et al. performed a thorough analysis of the benefits and drawbacks of illness severity score algorithms. The review brought attention to the SNAP scores' diminished ability to distinguish between the most preterm infants. Neonates with either BW and GA are eligible to use SNAPPE - II, which was created and is largely applied in the western developed places like US, Canada, whereas neonates with VLBW neonate are only eligible to use CRIB⁷, which was created in the United Kingdom and is primarily in Europe.

A prospective study by Maliheh Kadivar and colleagues was carried out in Tehran, Iran, from September 1, 2003, to August 28, 2004, and published in 2007. In this study, 213 neonates who had been admitted to the NICU were given the SNAPPE II score. 119 (60.1%) of the patients who underwent evaluation were male, with a mean age and SD of 7.6(0.5) days. The mean (SD) for birthweight was 2479.8 (29.4) grams, SNAPPE II score 21.6 (1.1), and Apgar scores at 1 minute were 7.47 (0.08) and 7.71 (0.06) at 5 minutes, respectively. The mean (SD) gestational age was 35.8 (0.2) weeks. The Chi-square test revealed that the gestational age (P=0.03) and birthweight (P=0.02) were very significant. Only SNAP and Apgar at 5 minutes may significantly predict neonatal mortality, according to an analysis using regression of logistics to determine the predictive value of these indicators for mortality. 42.1% of neonates who died had an Apgar score of less than 7 at 5 minutes. The neonatal mortality rate was 19.4% with a SNAPPE II score of greater than 19 points.

Another study was conducted on 191 neonates in Tehran, Iran, by Mitra Radfar et al. to determine the usefulness of the SNAP II and SNAPPE II scoring systems as indicators of the neonatal death rate, the current study was done. The difference between the mean age at admission (P = 0.037) and gestational age (P = 0.001) was statistically significant to 23. With the exception of the presence of seizures, all SNAP and SNAP II PE factors demonstrated a significant connection with neonates' survival (p = 0.001). According to the study, SNAP II has an

AUC of 0.992 and SNAPPE II has an AUC of 0.994, both of which have a very high predictive value for survival. The two methods had no statistically significant difference

Dhruba Shrestha performed a observational prospective research in Kathmandu , Nepal, where physiological information for the SNAP II and SNAPPE II score were gathered within 12 hours after admission. In a Nepal NICU with minimal resources, the goal of this study is to determine their effective use in predicting mortality . 29 (23.9%) of the 126 newborns involved in the study died. When SNAP II was >40, mortality was 83% (5/6) and 66.7% (6/9) when SNAPPE II was more than 50. For predicting mortality, a SNAP II score as 12 had a sensitivity and a specificity of 75.9% and 73.2% respectively , while a SNAPPE II score of 14 had a sensitivity of 82.8% and a specificity of 67.0%.

Data from emerging nations like India are scarce for CRIB II and SNAPPE II score validation. There is a need to evaluate the validity of these scores to predict mortality in diverse resource situations because the neonates clinical profile and their outcomes may vary in our scenario. This may facilitate prioritising neonates with illnesses and providing their parents with information about the severity of their conditions..

Methods and Materials

Study design: It is a prospective observational study.

Study setting: The study was done in the Department of Paediatrics, Shri B.M.Patil Medical

College Hospital And Research Centre, Vijayapura.

Study participants: All neonates admitted to LEVEL III A Neonatal Intensive Care Unit

(NICU), BLDE (Deemed to be University), Shri B. M. PATIL MEDICAL COLLEGE

HOSPITAL AND RESEARCH CENTRE, VIJAYAPUR, KARNATAKA who met inclusion

criteria for a period from Jan 2021 to June 2022.

Inclusion criteria:

Preterm neonates

i)Gestational ages between 26 to 34weeks.

ii)Birth weights from 500 to 2499 grams.

Exclusion criteria:

i) Gross congenital anomaly detected in the antenatal scan

ii) Neonates who were out of the hospital before the data collection was finished.

Number of groups to be studied: Two

Group 1 – Newborns who survived

Group 2 – Newborns who did not survive

63

Method of collection of Data

Low birth weight neonates admitted to NICU were enrolled to the study. Neonatal data including birth weight, gestational age, gender, temperature at admission were documented. The neonates were assessed at birth by APGAR @ 1 minute and 5 minutes, need for resuscitation at birth. The neonates admitted were monitored for temperature, blood pressure (MBP), seizures and urine output. Arterial blood gas analysis was done for all neonates enrolled and parameters were assessed. Need for inotropic support were assessed depending on vital parameters like heart rate, mean arterial pressure, ECHO findings. Neonatal outcomes at the time of discharge were assessed.

Scoring Parameter:

CRIB II scoring²⁸

- BW
- GA
- Gender
- Base Excess
- Temperature

SNAPPE-II scoring system ³¹

- MBP.
- Temperature.
- Serum pH.
- PaO2/FiO2 ratio.
- UO.
- Seizures.
- BW.
- GA.
- 5 minute Apgar score.

DocuSign Envelope ID: 1EE0B2C3-35A0-454D-92B4-AB980167C9DC

In this study, information like the Apgar score and history were recorded. Digital scales are

used to assess the weight of neonates. A temperature at admission was measured and recorded.

Neonates required oxygen via a hood, ventilators, or Continuous Positive Airway Pressure

machines were documented and FiO2 was noted which was necessary to maintain a normal SpO2.

Neonatal specialists examine neonates within the first 12 hours following birth to check for

congenital abnormalities.

Data analysis:

Sample size calculation

Assuming the anticipated population standard deviation to be 16.46, and applying t-

distribution to predicted sample size, the study employed a sample size of 264. To estimate a mean

with 95% confidence and a precision of 2. 54

Formula used: n = z2 S2

d2

Where Z=Z statistic at α level of significance

d2= Absolute error

P= Proportion rate

q = 100-p

65

Statistical Analysis

- The data obtained was entered in a Microsoft Excel sheet, and statistical analysis was estimated using a statistical package for the social sciences (Version 23).
- Results are presented as Mean (Median) ±SD, counts and percentages and diagrams.
- Categorical variables are compared using the Chi-square test. Odd's ratio (95% CI) is applied.
- ROC curve analysis, Yuden Index, predictive values were calculated.
- P < 0.05 is considered statistically significant.

THE WORK FLOW OF THE STUDY

Neonates admitted to NICU



Informed written consent was obtained from parent /attenders



Demographic details collected



History & Clinical assessment



Blood sampling and calculation of parameters



CRIB II scoring and SNAPPE II scoring



Additional laboratory investigations



Clinical outcome recorded (death / discharge)

RESULT

A total of 324 neonates were recruited in the study. The average birth weight of newborns admitted to NICU was 1760+/- 140 grams and the average gestation age was 32+/- 1 week (Table 1a).

Gestational of the neonates were divided into three groups 26 - 28 weeks, >28 - 32 weeks, >32 - 34 weeks. Among 283 survived neonates, maximum neonates was seen in groups between 28 - 32 (46.8%) weeks and 32 - 34(48.8%) weeks of gestation (Table 1b).

Neonates admitted in NICU were divided into 3 birthweight group. Among the 283 survived maximum survival was among LBW neonates (Table 1c).

Table 1a: Birthweight and Gestational age of neonates admitted to NICU

	N	Mean	Std. Deviation
Birth Weight	324	1757.08	1405.91
Gestation period	324	31.77	1.94

Table 1 b: Gestation Age of neonates admitted to NICU

POG	Not Survived (%)	Survived (%)
	N (33)	N (283)
26 – 28	9 (27.3%)	11 (3.9%)
>28 – 32	18(54.5%)	134(46.8%)
>32 – 34	6(18.2%)	138(48.8%)

Figure 11 : Gestation Age of neonates admitted to NICU $\,$




Table 1c: Birthweight of neonates admitted to NICU

Weight	Not Survived (%)	Survived (%)	
	(N=33)	(N=283)	
ELBW	13(39.3%)	13(4.6%)	
VLBW	11(33.3%)	94(33.2%)	
LBW	9(27.2%)	176(62.1%)	

Figure 11 b : Birthweight of neonates admitted to NICU




Table 1d: Sex distribution of Neonates admitted to NICU

		Neonatal Outcome	
		Not survived (%)	Survived (%)
		(N – 33)	(N=283)
Gender	Female	11 (33.4%)	130 (46.4%)
	Male	22(66.6%)	153(54%)

Figure 11c : Sex distribution of the neonates admitted to NICU




Table 2 : Mode of Delivery

			Neonatal Outcome			
		Not Survived				
		survived				
MODE OF	CAESAREAN	17	160	177		
DELIVERY	NORMAL	16	123	139		
	VAGINAL					

Figure 12 : Mode of delivery of the study group





Table 2 and Table 3. There was no significant difference between the neonates who survived and those who did not survive with respect to baseline maternal factors (Obstetric score, Gestational Diabetes Mellitus, Premature Rupture of Membranes (PROM), Maternal Thrombocytopenia, Maternal Fever, Maternal H/o Urinary Tract Infection, Maternal H/o Vaginitis or the mode of delivery) except for maternal PIH (Table 3). Similar observations were noted when neonates were stratified by different weight groups [<1000g, 1000-1500g, 1500-2000g, 2000-2499g].

Table 3: Baseline maternal factors between the neonatal groups

		Neonata				
		Not Sur	vived	Survived	d	
		Count	N %	Count	N %	P
						value
Gravida						
	->5	2	6.1%	7	2.5%	0.343
	1	15	45.5%	123	43.5%	0.528
	2	10	30.3%	70	24.7%	0.465
	3	4	12.1%	50	17.7%	0.312
	4	2	6.1%	24	8.5%	0.579
GDM status	No	33	100.0%	273	96.5%	0.607
	YES	0	0.0%	10	3.5%	
PROM status	No	26	78.8%	226	79.9%	0.822
	YES	7	21.2%	57	20.1%	
Maternal Thrombocytopenia	NO	33	100.0%	278	98.2%	0.974
	YES	0	0.0%	5	1.8%	
Maternal Fever	NO	32	97.0%	271	95.8%	1
	YES	1	3.0%	12	4.2%	
Maternal H/O UTI	No	33	100.0%	279	98.6%	0.902
	YES	0	0.0%	4	1.4%	
Maternal Chorioamnionitis	No	33	100.0%	281	99.3%	0.892
	YES	0	0.0%	2	.7%	
Maternal H/O Vaginitis	No	33	100.0%	277	97.9%	0.865

	YES	0	0.0%	6	2.1%	
PIH	No	15	45%	202	71%	0.005
	yes	18	55%	81	29%	

 ${\bf Figure 13a: Maternal\ gravida\ status\ in\ the\ study\ group}$






Figure 13b: Baseline maternal characteristics between neonatal group

Amongst neonates in NICU the average scores of APGAR at 1 min and 5 min were 6 & 8 respectively, CRIB II score was 5.1 and SNAPPE score was 12.7 as shown in **Table 4**.

Table 4: Summary Characteristics of neonates.

	N	Mean	Std. Deviation
APGAR SCORE : 1	324	6.694	.9777
minute			
APGAR SCORE : 5	324	8.648	.6534
minute			
SNAPPE – II	324	12.975	8.9442
CRIB – II	324	5.105	2.7465

Table 5 compares the important neonatal variable like birth weight, gestation period, APGAR score 1 and 5 minute, between those neonates who survived compared to those who didn't (6.8 vs 5.9 & 8.7 vs 8.2). The MAP recorded differed significantly between the two groups.

Table 5: Comparison of various neonatal variables between the two groups

	Neonatal	Neonatal outcomes							
	Not Survived			Survived	P				
					Value				
	Mean	N	Std.	Mean	N	Std.			
			Deviation			Deviation			
Birth Weight	1213.91	33.00	392.89	1830.48	283.00	1483.43	0.018		
(grams)									
Gestation period	30.00	33.00	2.32	31.99	283.00	1.80	< 0.001		
APGAR SCORE	5.91	33.00	1.23	6.79	283.00	.90	< 0.001		
: 1 minute									
APGAR SCORE	8.27	33.00	.88	8.70	283.00	.60	< 0.001		
: 5 minute									
Blood	31.45	33.00	2.40	33.10	283.00	2.07	<0.01		
pressure*(MAP)									
Urine output	5.92	33.00	29.46	2.77	283.00	15.56	0.550		
Body	34.63	33.00	1.24	35.24	283.00	4.37	0.071		
Temperature									

Table 6a: Comparison of birthweight between different groups

Weight		N	Mean	Std Deviation	Р
ELBW	NS	13	883	140	0.126
	S	13	1023	279	
VLBW	NS	12	1258	220	0.255
	S	89	1415	1146	
LBW	NS	9	1910	1861	0.038
	S	176	1980	1753	

Table 6b: Comparison of POG between different groups

POG (weeks)		N	Mean	Std Deviation	P
26 – 28	NS	9	27.22	0.972	0.539
	S	11	27.45	0.688	
>28-32	NS	18	30.22	1.06	0.041
20 32	S	134	30.80	1.01	0.011
>32 - 34	NS	6	33.50	0.548	0.952
	S	138	33.51	0.502	0.732

Neonates in LBW group had statistically significant difference between survived and not survived neonates in the study group (Table 6a)

In the study group 28-32 weeks neonates had better survival then 26-28 weeks. Statistically significant p value was seen in 28-32 weeks neonates in comparison to 32-34 weeks neonates. (Table 6b)

Table 6c: Outcome of neonates by gender

Gender		N	Mean	Std. Deviation	P
SNAPPE II	Female	144	13.0	9.1	0.975
	Male	180	13.0	8.9	
CRIB II	Female	144	4.9	2.3	0.165
	Male	180	5.3	3.0	

With regard to scoring systems for the neonates admitted to NICU **Table 6c, 7** presents the CRIB II score and SNAPPE II score of the neonates who did not survive and who survived. As can be seen from the table the scores were significantly differed between the two groups. Table 5c showed no difference outcome between male and female sex. The average CRIB II score in those who survived was **4.8** (vs not survived **7.2**) The average SNAPPE II score in those who survived was **11.2** (vs not survived **25.4**).

Table 7: Comparison of CRIB II and SNAPPEII scores between the two groups

	Neonatal Outcome									
	Not surv	ived		Survived	P Values					
	Mean	N	Std.	Mean	N	Std.				
			Deviation			Deviation				
SNAPPE II*	25.4	33.0	9.2	11.2	283.0	7.4	<0.0001			
CRIB II*	7.2	33.0	3.5	4.8	283.0	2.6	<0.0001			

^{*}p<0.0001

There was no significant difference between the two groups with respect to other parameters pH, pO2, pCO2, bicarbonate levels, White blood cells, platelets, urine output and use of an inotrope (**Table 8**). However base excess values differed significantly between the groups. The results of various neonatal and maternal factors between the two groups were similar to the tables above when stratified by different weights.

 $Table\ 8\ Comparisons\ of\ clinical\ and\ laboratory\ parameters\ between\ the\ two\ groups$

Parameters	Not survived				Survived	1	P value
	Mean	N	SD	Mean	N	SD	
White Blood	10937.9	33.0	6414.6	11608.0	283.0	7668.4	0.581
Cells							
Platelets	211884.4	32.0	87792.4	249862.5	283.0	149138.2	0.159
pН	7.3	33.0	.1	7.8	283.0	5.6	0.101
pCO2	32.1	33.0	13.3	32.0	283.0	23.1	0.955
pO2	138.5	33.0	48.0	130.9	283.0	41.7	0.389
НСО3	13.8	33.0	3.8	16.2	283.0	11.7	0.247
Lactate	9.6	33.0	29.2	4.5	283.0	3.3	0.451
Base excess*	10.2	33.0	4.0	8.2	283.0	4.3	0.010
NPO	41.5	33.0	19.7	45.4	283.0	23.2	0.210

Comparison between groups following Stratification by birthweight

The neonatal factors birthweight, gestation, APGAR scores (1 & 5 min), CRIB II and SNAPPE II were compared between the two groups stratified by different categories of birth weight. Category A <1000g, Category B – 1001-1500g, Category C-1501-2000g and Category D- 2001 -2499g.

Table 9A compares the scores in those neonates who weighed <1000 g. SNAPPE II scores differed significantly between the two groups. For other scores there was no significant difference between those who survived vs those who didn't. Table 9 B depicts the scores in those neonates weighing 1001-1500g. Again, the only score to differ between the groups was SNAPPE - II while rest all the scores were not statistically significant between the two groups. Table 9C shows the scores of neonates weighing 1501-2000g. SNAPPE - II differed between the two groups (p=0.012) while other scores did show any statistically significant difference between the groups. For neonates weighing 2001-2499g none of the scores differed between the groups.

Table 9 A: Comparison of scores for Birth weight <1000grams.

Out come status	N	Mean	Std.	P value	
				Deviation	
Birthweight	Not Survived	13	883.615	140.3624	0.126
	Survived	13	1022.923	279.1235	
Gestation period	Not Survived	13	28.77	2.088	0.514
	Survived	13	28.69	1.750	
APGAR SCORE : 1	Not Survived	13	5.846	1.1435	0.417
minute	Survived	13	6.462	.7763	
APGAR SCORE : 5	Not Survived	13	8.077	.9541	0.184
minute	Survived	13	8.538	.6602	
SNAPPE II*	Not Survived	13	31.385	5.6795	<0.001
	Survived	13	16.846	6.6061	
CRIB II	Not Survived	13	9.462	3.2046	0.503
	Survived	13	8.769	1.7867	

^{*} p<0.0001

Table 9 B: Comparison of scores for Birth weight = 1001 to 1500grams.

Out come status			Std.	P value
			Deviation	
Not Survived	12	1258.667	220.6920	0.255
Survived	89	1415.933	1146.0994	
Not Survived	12	29.42	1.379	0.004
Survived	89	30.89	1.563	_
Not Survived	12	6.000	.9535	0.08
Survived	89	6.551	.9172	
Not Survived	12	8.417	.6686	0.09
Survived	89	8.528	.6923	
Not Survived	12	23.250	8.9048	0.002
Survived	89	12.798	8.2987	
Not Survived	12	7.083	2.8110	0.162
Survived	89	5.809	2.8118	
	Survived Not Survived Not Survived	Survived 89 Not Survived 12 Survived 12	Not Survived 12 1258.667 Survived 89 1415.933 Not Survived 12 29.42 Survived 89 30.89 Not Survived 12 6.000 Survived 89 6.551 Not Survived 12 8.417 Survived 89 8.528 Not Survived 12 23.250 Survived 89 12.798 Not Survived 12 7.083	Not Survived 12 1258.667 220.6920 Survived 89 1415.933 1146.0994 Not Survived 12 29.42 1.379 Survived 89 30.89 1.563 Not Survived 12 6.000 .9535 Survived 89 6.551 .9172 Not Survived 12 8.417 .6686 Survived 89 8.528 .6923 Not Survived 12 23.250 8.9048 Survived 89 12.798 8.2987 Not Survived 12 7.083 2.8110

^{*} p<0.0001

Table 9 C: Comparison of scores for Birth weight = 1501 to 2000grams.

Out come status		N	Mean	Std.	P value
				Deviation	
Birthweight (grams)	Not Survived	7	1566.857	182.1789	0.559
	Survived	112	1891.214	1456.2790	
Gestation period	Not Survived	7	32.71	1.113	0.600
	Survived	112	32.47	1.329	
APGAR SCORE : 1	Not Survived	7	5.857	1.9518	0.188
minute	Survived	112	6.955	.7400	
APGAR SCORE : 5	Not Survived	7	8.429	1.1339	0.407
minute	Survived	112	8.813	.4938	
SNAPPE II*	Not Survived	7	17.143	8.0711	0.012
	Survived	112	10.455	6.6304	
CRIB II	Not Survived	7	3.714	1.6036	0.567
	Survived	112	4.196	2.1803	

^{*} p<0.05

Table 9 D: Comparison of scores for Birthweight = 2001 to 2499 grams.

Out come status		N	Mean	Std.	P value
				Deviation	
Birthweight (grams)	Not Survived	1	2500.000		0.973
	Survived	64	2435.063	1867.7631	
Gestation period	Not Survived	1	34.00		0.514
	Survived	64	33.30	1.064	
APGAR SCORE : 1	Not Survived	1	6.000		0.417
minute	Survived	64	6.875	1.0616	
APGAR SCORE : 5	Not Survived	1	8.000		0.184
minute	Survived	64	8.781	.5765	
SNAPPE II	Not Survived	1	31.000		0.002
	Survived	64	9.063	6.8264	
CRIB II	Not Survived	1	5.000		0.510
	Survived	64	3.859	1.7078	

P value : < 0.05


Gestation Age, Birth Weight as a predictor of mortality

Considering the study population birthweight and gestational age individually were poor predictor of mortality (AUC 0.2 & 0.25 respectively). The lower limit of the confidence interval for the both parameters is around 0.1 signifying poor predictive ability of these parameters. (Tables 10 & 11, Figures 1 & 2)

Table 10: Area Under the Curve – Birth Weight

Test	Result	Birth Weight		
Variable(s):				
Area		Std. Error ^a	Asymptotic	95%
			Confidence In	nterval
			Lower	Upper
			Bound	Bound
.201		.042	.119	.283

Figure 14 – ROC Curve – Birth Weight




AUC:0.201

Table 11: Area Under Curve - Gestation

Test	Result	Gestation period		
Variable(s):				
Area		Std. Error ^a	Asymptotic	95%
			Confidence In	nterval
			Lower	Upper
			Bound	Bound
.253		.049	.156	.350

Figure 15: ROC Curve - Gestation



AUC:0.253

CRIB – **Predictor** of **Mortality**

The CRIB score of the newborns that did not survive varied from 0 to 13, presenting an average score of 7.2 ± 3.4 . The score of those that survived varied from 0 to 20, with an average of 4.8 ± 2.5 . The difference between these scores was not statistically significant (p=0.69). Though the AUC for predicting mortality is 0.72 but the value of lower bound of the AUC is 0.61 implying poor predictive ability. The results stratified by birth weight categories are presented in the subsequent pages. The **table 12A & figure 16** shows that a cut off > 5.5 has 64% sensitivity and 74% specificity in predicting mortality.

Table 12: Area Under Curve – CRIB II

Test Result Variable(s):	CRIB 2		
Area	Std. Error ^a	Asymptotic 95	5% Confidence
		Interval	
		Lower Bound	Upper Bound
.725	.057	.614	.836

Table 12 A: Coordinates of the Curve


Test Result Variable(s):

	variable(b).	
Positive if Greater Than or Equal To ^a	Sensitivity	1 - Specificity
-1.000	1.000	1.000
.500	.970	.986
1.500	.939	.986
2.500	.879	.908
3.500	.848	.707
4.500	.788	.413

5.500	.636	.261
6.500	.606	.173
7.500	.545	.141
8.500	.394	.092
9.500	.333	.057
10.500	.152	.032
11.500	.121	.014
12.500	.030	.007
16.500	0.000	.007
21.000	0.000	0.000

The test result variable(s): CRIB II

Figure 16: ROC Curve – CRIB II



Diagonal segments are produced by ties.

AUC 0.725

SNAPPE II as a predictor of mortality

The neonates that did not survive had SNAPPE II scores ranging from 5 to 45, with an average score of 25 ± 9 . The score of those that survived varied from 0 to 32, with an average of 11 ± 7 . The difference between these scores was statistically significant (p<0.001). Though the AUC for predicting mortality is 0.88 and width of the Confidence limits are narrow implying good predictive ability. The results stratified by birth weight categories are presented in the subsequent pages. The **table 13A & figure 17** shows that a cut off 17.5 and above has **78%** sensitivity and **82%** specificity in predicting mortality in neonates born before the age of 34 weeks irrespective of birthweight status.

Table 13: Area Under Curve – SNAPPE II

Area	Std. Error ^a	Asymptotic 9:	5% Confidence
		Interval	
		Lower Bound	Upper Bound
.879	.034	.813	.946

Table 13 A: Coordinates of the Curve


Test Result Variable(s):

Positive if Greater Than or Equal To ^a	Sensitivity	1 - Specificity
-1.000	1.000	1.000
1.000	1.000	.890
2.500	1.000	.887
3.500	1.000	.880
4.500	1.000	.876
5.500	.970	.717
6.500	.970	.707

7.500	.970	.693
8.500	.970	.565
9.500	.970	.527
11.000	.909	.431
12.500	.909	.424
14.000	.818	.300
15.500	.818	.251
16.500	.818	.237
17.500	.818	.226
18.500	.758	.184
19.500	.758	.180
20.500	.667	.113
22.000	.667	.106
23.500	.667	.074
24.500	.667	.071
25.500	.576	.028
26.500	.576	.021
27.500	.455	.018
28.500	.394	.011
29.500	.394	.007
30.500	.364	.007
31.500	.273	.007
33.000	.152	0.000
35.000	.121	0.000
36.500	.061	0.000
41.000	.030	0.000
46.000	0.000	0.000
TD1	alt reominable (a)	CNIADDE

The test result variable(s): SNAPPE II has at least one tie between the positive actual state group and the negative actual state group.

Figure 17: ROC Curve – SNAPPE II




AUC:0.879

Comparing Gestation age, Birth weight, CRIB II and SNAPPE II.

The scoring systems and other factors are analysed using ROC curves.(figure 18). With a significant difference in AUCs, SNAPPE II had a higher AUC for predicting mortality than CRIB-II: 0.88 (95% confidence interval CI: 0.82 - 0.95) vs. 0.7 (95%. CI: 0.62. - 0.8). Better discriminatory ability was enabled by the SNAPPE II grading system. (Figure 18).

Figure 18: ROC Comparing all the parameters in the whole study population



Predictive role of Scoring systems in different weight categories

Very low birth neonates

When compared to CRIB-II, SNAPPE II showed a higher AUC in very low birth neonates, with a significant difference between the two AUCs of 0.8 (95% confidence interval CI: 0.68-0.93) vs. 0.7 (95% confidence interval CI: 0.5-0.8). SNAPPE II scoring system had better discriminatory ability (Table 14 & Figure 19). A close look on coordinates from table 14A & figure 19 shows that a CRIB II cut off score of 6.5 and above has 83% sensitivity and 73% specificity in predicting mortality. While SNAP PE II cut off score of 17.5 and above has 75% sensitivity and 68% specificity in predicting mortality in very low birth infants. As can be seen from the figure 6 both the gestation age and birth weight were poor predictors of mortality in sub group of neonates.

Table 14: Area Under the Curve- (1001g- 1500g) SNAPPE II, Birth Weight, Gestation period, CRIB II

Test Result	Area	Std. Error ^b	Asymptotic	Asymptotic	95%
Variable(s)			Sig. ^c	Confidence I	Interval
				Lower	Upper
				Bound	Bound
SNAPPE II	.805	.065	.001	.677	.933
Birth	.458	.115	.640	.232	.684
Weight					
Gestation	.245	.072	.004	.105	.385
period					
CRIB II	.708	.091	.020	.531	.886

Figure 19: ROC Curve all the parameter in very low birth neonates.




Table 14 A: Coordinates of the Curve^a

Test Result Variable(s)	Positive if Greater Than or Equal To ^b	Sensitivity	1 - Specificity
SNAPPE	-1.000	1.000	1.000
SNAPPE II	1.000	1.000	.899
	2.500	1.000	.888
	4.000	1.000	.876
	5.500	1.000	.787
	6.500	1.000	.764
	7.500	1.000	.742
	8.500	1.000	.618
	9.500	1.000	.607
	11.000	.833	.517
	12.500	.833	.506
	14.000	.750	.360
	16.000	.750	.337

17.500
Birth Weight 999.000 1.000 1.000 1.000 1.026.500 .750 .989 1056.500 .750 .950 1.075.000 .750 .950 1.075.000 .750 .950 1.075.000 .750 .950 1.090.000 .750 .950 1.090.000 .750 .950 1.090.000 .750 .950 1.090.000 .750 .950 1.090.000 .750 .950 1.090.000 .750 .950 1.090.000 .750 .950 1.090.000 .750 .950 1.090.000 .750 .950 1.090.000 .750 .950 1.090.000 .750 .950 1.090.000 .750 .950 1.090.000 .750 .950 1.090.000 .750 .950 1.090.000 .750 .950 1.090.000 .750 .950 1.090.000 .750 .930 1.090.000 .930 1.090 1.0
22.000 .583 .146
Birth Weight 999.000 1.000 1.000 1.026.500 .750 .989 1056.500 .750 .950 1067.000 .750 .950 1090.000 .750 .955 1090.000 .955 1090.0000 .955 1090.000 .955 1090.000 .95
Birth 999,000 1.000 1.000 1.066.500 .750 .988 1062.000 .750 .950 1075.000 .750 .950 1090.000 .750 .950 1090.000 .750 .955 1090.000 .955 1090.0000 .955 1090.0000
Birth Weight 999.000 1.000 1.000 1.000 1.000 1.065.500 .750 .985 1067.000 .750 .955 1075.000 .750 .955 1090.000 .750 .955 1090.000 .750 .945 1090.000 .750 .935 1090.000 .750 .945 1090.000 .750 .935 1090.000 .750 .945 1090.000 .750 .935 1090.000 .935 1090.0000 .935 1090.0000 .935 1090.000 .935 1090.
Birth Weight 999.000 1.000 1.000 1.062.000 7.50 989 1062.000 7.50 989 1075.000 7.50 989 1075.000 7.50 9.95 1075.000 7.50 9.95 1075.000 7.50 9.95 1090.000 9.75 1090.000 9.95 1090.000 9.75 1090.000 9.95 1090.000 9.75 1090.000 9.95 1090.000 9.0
30.000 .250 .022 34.000 .083 0.000 37.000 0.000 0.000 Birth 999.000 1.000 1.000 1026.500 .750 .989 1056.500 .750 .978 1062.000 .750 .960 1067.000 .750 .955 1075.000 .750 .944 1090.000 .750 .933
Birth 999,000 1.000 1.000 Weight 1026.500 .750 .985 1062.000 .750 .965 1075.000 .750 .955 1090.000 .750 .965 1090.000 .750 .965 1090.000 .750 .965 1090.000 .750 .965 1090.000 .750 .965 1090.000 .750 .965 1090.000 .750 .935
Birth Weight 999,000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.056.500 1.750
Birth Weight 999.000 1.000 1.000 1026.500 .750 .989 1056.500 .750 .978 1062.000 .750 .960 1067.000 .750 .955 1075.000 .750 .944 1090.000 .750 .933
Weight 1026.500 .750 .989 1056.500 .750 .978 1062.000 .750 .960 1067.000 .750 .955 1075.000 .750 .944 1090.000 .750 .935
1056.500 .750 .978 1062.000 .750 .966 1067.000 .750 .955 1075.000 .750 .944 1090.000 .750 .933
1062.000 .750 .960 1067.000 .750 .955 1075.000 .750 .944 1090.000 .750 .933
1067.000 .750 .955 1075.000 .750 .944 1090.000 .750 .933
1075.000 .750 .944 1090.000 .750 .933
1090.000 .750 .933
1105.000 .583 .820
1115.000 .583 .809
1130.000 .500 .798
1145.000 .500 .775
1155.000 .500 .753
1165.000 .500 .719
1185.000 .500 .697
1219.500 .500 .596
1239.500 .500 .584
1270.000 .500 .573
1310.000 .500 .483
1335.000 .500 .472
1355.000 .500 .438
1375.000 .500 .421
1392.500 .500 .404
1397.500 .500 .393
1407.000 .333 .213
1424.500 .333 .202
1442.500 .333 .193
1455.000 .333 .157
1472.000 .333 .135
1487.000 .250 .135
1495.000 .250 .112
1538.000 0.000 .034
1738.000 0.000 .022
6951.000 0.000 .011
12003.000 0.000 0.000
Gestation 26.00 1.000 1.000 period 25.00 1.000
27.50 .917 .989
28.50 .750 .955

	29.50	.500	.843				
	30.50	.167	.528				
	31.50	.083	.337				
	32.50	0.000	.169				
	33.50	0.000	.067				
	35.00	0.000	0.000				
CRIB II	-1.000	1.000	1.000				
	1.000	.917	.978				
	2.500	.917	.944				
	3.500	.833	.854				
	4.500	.833	.685				
	5.500	.833	.494				
	6.500	.833	.270				
	7.500	.667	.213				
	8.500	.250	.124				
	9.500	.083	.090				
	10.500	0.000	.056				
	11.500	0.000	.034				
	16.000	0.000	.011				
	21.000	0.000	0.000				
The test regult veriable(s): SNADDE II Dirth							

The test result variable(s): SNAPPE II, Birth Weight, gestation period, CRIB II has at least one tie between the positive actual state group and the negative actual state group.^a
a. BIrth weight = 1001 to 1500g


Extremely low birth weight neonate

In extremely low birth neonates only CRIB II had higher AUC compared with other parameters AUC: 0.6 (95% confidence interval CI: 0.45–0.89) having significant difference between AUCs. A close look on coordinates from **table 15 & figure 20** shows that a CRIB II cut off score of 9.5 and above has 77% sensitivity and 62% specificity in predicting mortality. As can be seen from the figure 7 both the gestation age and birthweight were poor predictors of mortality in sub group of neonates.

Table 15: Area Under the Curve - (<1000g)SNAPPE II, Birth Weight, Gestation period, CRIB II.

Test Result	Area	Std. Error ^b	Asymptotic	Asymptotic	95%
Variable(s)			Sig. ^c	Confidence Interval	
				Lower	Upper
				Bound	Bound
SNAPPE	1.000	0.000	.000	1.000	1.000
II					
Birth	.441	.120	.608	.205	.677
Weight					
Gestation	.506	.117	.959	.277	.735
period					
CRIB II	.672	.113	.137	.450	.893

Figure 20: ROC curve all the parameters in extremely low birth weight neonates



Low birth weight neonates

For predicting mortality in low birthweight neonates SNAPPE II Scores provided better information compared to other parameters. (AUC -0.75, CI: 0.5 to 0.90). The other parameters did not predict well. As can be seen from Figure 21, a SNAPPE II score of 11.5 resulted in a sensitivity of 85% and a specificity of 58%.

Table 16: Area Under the Curve-(1501g- 2000g)SNAPPE II, Birth Weight, Gestation period, CRIB II.

Test Result	Area	Std. Error	Asymptotic	Asymptotic 95%	
Variable(s)			Sig.	Confidence Interval	
				Lower	Upper
				Bound	Bound
SNAPPE II	.745	.099	.030	.551	.939
Birthweight	.232	.057	.018	.121	.343
Gestation	.532	.108	.778	.321	.743
period					
CRIB II	.509	.127	.937	.260	.757

Figure 21: ROC curve all the parameters in low birth weight neonates (1501-20




Table 17: Comparison of Gestational age between CRIB II and SNAPPE II

POG	CRIB II		SNAPPE II			
Weeks	AUC	Sensitivity	Specificity	AUC	Sensitivity	Specificity
26 – 28	0.540	44%	64%	0.798	66%	95%
28 – 32	0.737	61%	80%	0.854	78%	79%
32 – 34	0.679	80%	40%	0.894	66%	90%

CRIB II score had good predictive ability for neonates with gestation age of 28-32 weeks with specificity of 80%, neonates with 32-34 weeks had 80% sensitivity but specificity was 40%; only as there is no standardized scoring system for neonates above 32 weeks in CRIB II scoring system.

SNAPPE II score had good predictive ability for neonates in all three subgroups.

Sensitivity and specificity for 26 - 28 weeks was 66% and 95%, 28 -32 weeks 78% and 79%, 32 -34 weeks 66% and 90% respectively. Implying SNAPPE II had good predictivity in all preterm neonate category in the study.

Table 18: Comparison on birth weight between CRIB II and SNAPPE II

Weight	CRIB II		SNAPPE II			
	AUC	Sensitivity	Specificity	AUC	Sensitivity	Specificity
ELBW	0.672	76%	62%	0.95	84%	95%
VLBW	0.708	66%	79%	0.805	75%	68%
LBW	0.509	72%	34%	0.745	85%	58%

Comparison of the two score CRIB II and SNAPPEII among birthweight categories showed good sensitivity and specificity in both the groups for ELBW (76%,62%) vs (84%,95%), VLBW (66%,79%) vs (75%,68%) respectively, whereas in LBW neonates CRIB II sensitivity was 72% but specificity was low 34% but SNAPPE II had comparatively good sensitivity and specificity for this group of neonates too i.e 85% and 58% respectively.

DISCUSSION

The study evaluated predictive role of scorings systems CRIB-II and SNAP PE II in 324 pre term infants at tertiary care hospital from South India with a special focus on very low birthweight neonates.

The mean SNAP PE II scores were significantly higher in neonates who expired compared to those who survived (25.4 vs 11.2). The SNAP PE II score was noted to be high in neonates who died in Category B (BW 1001 to 1500g) and Category C (BW 1501 to 2000g) but not in Category A (BW) < 1000g) & Category D (BW 2001 to 2499g) which we attribute to the small number of neonates included from this group. Analysis of the ROC curve for SNAPPE II showed an area under the curve with moderate values for Category B (**Table 14, AUC - 0.8**).

The CRIB II scoring also showed a significant predictive ability only in Category B (BW) < 1000g]) [**Table 14, AUC -0.7**] and was not significant in other weight groups. In the ELBW neonates CRIB II was only scoring parameter which performed better compared to other variables (**Table 15, AUC – 0.67**)

The score had superior discriminatory capacity than birthweight alone (Az = 0.78) in the original study that led to the establishment of CRIB (area under the ROC curve: Az = 0.90).²⁷ In comparison the present study reports lower discriminatory ability for CRIB II scoring in both very low birthweight neonates and pre term neonates . The possible explanation could be lesser number of neonates included from that extremely low birth weight category. The simplicity of CRIB's data collection is a major benefit, as each neonate's calculation only takes five minutes, as opposed to 20- or 30-minute calculations for some of the more difficult scores, such SNAP, SNAP-PE..⁵

Problems like Fio2 use and data collection upto 12 hours of admission were avoided in CRIB II. Dalili et al assessed CRIB II and SNAP PE II for predicting mortality in preterm (<32 weeks) or low birthweight neonates (<1500 g) admitted to NICU in Iran and reported a cut-off of 27.5 for SNAPPE II with sensitivity and specificity of 84% and 79% respectively and reported accuracy of 0.887 (CI 95%:0.847- 0.927) (P<0.05). In contrast the present study includes all newborns below the gestational age of 34 weeks.

The cut off obtained in the present study for SNAPPE II is also lower (17.5) and sensitivity and specificity being 78% and 82% respectively (Table 14 A) while the values reported for sensitivity and specificity by Dalili et Both are 79.05% (CI 95%: 79.051-79.052) and 84.44% (CI 95%: 84.443-84.445) with a cut-off point of 27.5, respectively. Additionally, at the cut-off point of 29 +/- 5, these similar values were 82.22% (CI 95%: 82.222 - 82.223) and 81.42% (CI 95%: 81.422 - 8.423). The same study reported a cut off point of 8.5 for CRIB II system with a sensitivity and specificity of 74.4% and 78.65% respectively. In comparison our study has reported a CRIB cut off value of 6.5 with 64% sensitivity and 74% specificity.

In Richardson's et al comparison, SNAP predicted death better than birth weight alone (Az 0.87 v 0.77), and SNAP-PE was even better (Az 0.93). In comparison the AUC obtained in the present study are on lower range.

Comparison with other studies

Thimoty *et al* evaluated SNAPPE II as the predictor of neonatal mortality in NICU at a general hospital Indonesia reported a good correlation between SNAPPE II and mortality and suggested a cut-off of 51. This cut off seems several times higher than the cut off obtained in the current study (17.5). The AUC reported in that study was (0.933, 95% CI- 0.843-1) was high compared to our study.

Our study is similar to a study done in Nepal by Muktan et al where SNAPPE-II score validity as neonatal mortality predictor and length of stay in NICU was evaluated. It was found that the cut-off score 38 for predicting mortality, sensitivity 84.4% and specificity 91%9. In comparison to the newborns that survived, the babies who died had significantly higher median (IQR) SNAP PE II scores [57 (42 - 64) vs. 22 (14 - 32), P 0.001]. The ROC curve's area under the curve (AUC) was 0.917 (95% CI: 0.854-0.980). The best cut off SNAPPE-II score in predicting overall mortality was 38. Sensitivity, specificity, positive and negative predictive value of score ≥ 38 in estimating overall mortality were 84.4, 91, 66.7 and 96.5% respectively. Though the cut offs are slightly higher implication is similar to our study.

A prospective study by Eldin from Egypt reported with a cut-off point of 11, the CRIB II score is a reliable measure for LBW risk assessment initially and had good specificity (82.4%) and high sensitivity (94.9%)7. Additionally, ROC curve analysis showed that the optimal cut-off for predicting death were 11 for CRIB II score, 28 for gestational age, and 1100 for birthweight. These values had the best sensitivity and specificity. While the age and gestation were poor predictors of mortality in our study the cut off value for CRIB II was **6.5.** Our findings are in agreement with Eldin et al. study results , who observed that the CRIB II score had the best accuracy for extremely low birth children (86.7%).

The SNAPPE II scoring results obtained in our study are similar to a multicentric study in the Indian population by Vardhelli *et al* who compared SNAP PE II score and CRIB-II score in neonate illness severity scores assessment for mortality and morbidity prediction in neonates with gestational age of \leq 32 weeks and found good predictive ability for in hospital mortality with SNAPPE-II (AUC: 0.78)³⁹. In contrast our study did not find significant predictive ability for CRIB II for pre term as a whole. Unlike study by Vardhelli we found dissimilar AUC with CRIB-II and SNAPPE-II. Our observations are in agreement with the results of a study by Eldin et al., who observed that the CRIB II score had the best accuracy (the percentage of true results, including true positives and true negatives) for extremely low birth children (86.7%).

In a study conducted by Harsha and Archana SNAPPE-II score of 37 or higher was associated with an increased death rate, which is once more higher than what our study⁸ reported. However, unlike Harsha's study, our attention was limited to only preterm infants. They claimed that, regardless of gestational ages, SNAPPE-II demonstrated a good connection with outcomes in terms of mortality. In this study, increased mortality was linked to SNAPPE-II scores of 37 and above.

Gagliardi *et al* evaluated the propensity for CRIB, CRIB-II, and SNAPPE-II to predict in-hospital mortality in a cohort of VLBW neonates admitted to 12 NICUs taking part in a regional area in Italy between 1999 and 2001, and found that CRIB and CRIB-II exhibited more discrimination than SNAPPE-II (AUC 0.90 and 0.91 vs 0.84,)⁶. However, these figures are before the advent of ante natal steroids and surfactants. So retrospective AUC comparison may not be appropriate. Unlike their study we did not find any association between caesarean section and survival.

SNAPPE (devised and primarily used in the United States and Canada) is used in neonates of all birth weight and all GA, whereas CRIB II (designed in the United Kingdom and

mainly employed in Europe) can only be applied to VLBWI. The practice is heterogenous in the Indian setting with several scores being used.

There could be several reasons for the different cut off, AUC, sensitivity and specificity values compared to other studies. The sample had a relatively less number of children below 1000 g. Accordingly the results of scoring systems obtained from this category could only be an estimate.

Strengths

The study is conducted in large group of pre term infants (324). Other studies which have evaluated scoring system from developing countries have been conducted smaller group of children.

There is some uncertainty with the regard to the application of CRIB II scoring in different classes of low birthweight patients. The current study found significant application for CRIB -II scoring only in the category B (BW- 1000- 1500) but not in other groups. Whereas SNAPPE II system can be applied in all the age groups except Category A (BW< 1000).

Limitations

The number of infants in some of the weight categories (Extremely low birth weight) were relatively less in comparison to other weight categories. The actual outcomes (death and survival) were again few in some of the sub groups. This could be because of a higher quality of care being provided so that lesser number of infants are dying.

Implications

The study of scoring system has to be evaluated based on the clinical profile of neonates and in a different resource setting. This may facilitate prioritising neonates with illnesses and providing their parents with information about the severity of their conditions. The validity of scoring systems furthers helps in planning NICU manpower, training, optimizing the utilizations of resources.

SUMMARY

- In the study population of 324 neonates, the average birth weight of neonates admitted to the NICU was 1760 grams and the gestation period was 32 weeks. Between groups that survived and those that did not, there was no significant difference in terms of baseline maternal characteristics except that pregnancy-induced hypertension had significant value among the maternal complications.
- Blood pressure recording among the neonates had significant differences among the two groups compared to other base neonatal variables.
- Base excess values differed between the two groups compared to laboratory parameters between the two groups of neonates.
- Among neonates admitted in our NICU, mean CRIB II 5.1 and SNAPPE II -12.7. The score in neonates who survived was 4.8 in CRIB II and 11.2 in SNAPPE II.
- CRIB II and SNAPPE II scores on application to different birthweight showed a significant difference between the groups. SNAPPE was more reliable without any distinction between survived and not survived neonates.
- Individually birth weight and gestational age are poor mortality predictors.
- SNAPPE II score had a better predictive potential of mortality among neonates born before 34 weeks, irrespective of the birth weight.
- SNAPPE II has better predictivity of mortality among neonates admitted to NICU in terms of both birth weight and gestational age considered.
- SNAPPE II score differed significantly from the CRIB II score in neonates more than 2000g and more than 32 weeks of gestation.

- CRIB 2 scoring system had good predictivity for neonates between 28 32 weeks with a sensitivity of 61%, specificity of 80% and for less than 1500 grams as 66% sensitivity and 79% specificity.
- SNAPPE II had better sensitivity and specificity for neonates till 34 weeks of gestation and 2500 grams.
- SNAPPE II predictive scores for extreme preterm were better than CRIB II, with sensitivity and specificity of 95% and 64%, respectively.
- Survival rates of neonates between 28-32 and 32-34 weeks were significant, with statistically significant in 28-32 weeks implementing good NICU care
- CRIB II scoring had good predictive ability in neonates between 26 to 32 weeks of
 gestation in terms of sensitivity and specificity but to lack of standardization of score for
 neonates above 32 weeks; CRIB II score is not applicable to neonates above 32 weeks.
- SNAPPE II score has good mortality predictor ability in all preterm neonates between
 26 to 34 weeks of gestation and low birthweight groups SNAPPE II has better
 sensitivity and specificity in all groups studied.

CONCLUSION

- Depending on the outcomes, it can be concluded that the SNAPPE II score is a suitable tool for estimating mortality in neonates with very low birthweights and gestations between 28 and 32 weeks.
- SNAP PE II score is a more accurate predictor of neonatal mortality than the CRIB II score.
- Compared to birthweight and gestational age alone, CRIB-II and SNAPPE II both superior predictors of the outcome of mortality.

BIBLIOGRAPHY

- 1. McCormick MC. The contribution of low birth weight to infant mortality and childhood morbidity. N Engl J Med. 1985 Jan 10;312(2):82–90.
- Newborn Mortality [Internet]. [cited 2022 Oct 29]. Available from: https://www.who.int/news-room/fact-sheets/detail/levels-and-trends-in-child-mortality-report-2021
- 3. Tarnow-Mordi W, Ogston S, Wilkinson AR, Reid E, Gregory J, Saeed M, et al. Predicting death from initial disease severity in very low birthweight infants: a method for comparing the performance of neonatal units. BMJ. 1990 Jun 23;300(6740):16114
- 4. Patrick SW, Schumacher RE, Davis MM. Methods of mortality risk adjustment in the NICU: a 20-year review. Pediatrics. 2013 Mar;131 Suppl 1:S68-74.
- 5. Dorling J, Field D, Manktelow B. Neonatal disease severity scoring systems. Arch Dis Child Fetal Neonatal Ed. 2005 Jan;90(1):F11–6.
- 6. Gagliardi L, Cavazza A, Brunelli A, Battaglioli M, Merazzi D, Tandoi F, et al. Assessing mortality risk in very low birthweight infants: a comparison of CRIB, CRIB-II, and SNAPPE-II. Arch Dis Child Fetal Neonatal Ed. 2004 Sep;89(5):F419-422.
- 7. Ezz-Eldin ZM, Hamid TAA, Youssef MRL, Nabil HED. Clinical Risk Index for Babies (CRIB II) Scoring System in Prediction of Mortality in Premature Babies. J Clin Diagn Res JCDR. 2015 Jun;9(6):SC08-11.
- 8. Harsha SS, Archana BR. SNAPPE-II (Score for Neonatal Acute Physiology with Perinatal Extension-II) in Predicting Mortality and Morbidity in NICU. J Clin Diagn Res JCDR. 2015 Oct;9(10):SC10-12.
- 9. Muktan D, Singh RR, Bhatta NK, Shah D. Neonatal mortality risk assessment using SNAPPE- II score in a neonatal intensive care unit. BMC Pediatr. 2019 Aug 13;19(1):279.
- 10. Rachuri S, Paul S, D JM. SNAPPE II score: predictor of mortality in NICU. Int J Contemp Pediatr. 2019 Feb 23;6(2):422–6.
- 11. Quinn JA, Munoz FM, Gonik B, Frau L, Cutland C, Mallett-Moore T, Kissou A, Wittke F, Das M, Nunes T, Pye S, Watson W, Ramos AA, Cordero JF, Huang WT, Kochhar S, Buttery

- J; Brighton Collaboration Preterm Birth Working Group. Preterm birth: Case definition & guidelines for data collection, analysis, and presentation of immunisation safety data. Vaccine. 2016 Dec 1;34(49):6047-6056. doi: 10.1016/j.vaccine.2016.03.045. Epub 2016 Oct 13. PMID: 27743648; PMCID: PMC5139808.
- 12. Preterm birth [Internet]. [cited 2022 Oct 29]. Available from: https://www.who.int/news-room/fact-sheets/detail/preterm-birth
- 13. Blencowe H, Krasevec J, Onis M de, Black RE, An X, Stevens GA, et al. National, regional, and worldwide estimates of low birthweight in 2015, with trends from 2000: a systematic analysis. Lancet Glob Health. 2019 Jul 1;7(7):e849–60.
- 14. Beck S, Wojdyla D, Say L, Betran AP, Merialdi M, Requejo JH, et al. The worldwide incidence of preterm birth: a systematic review of maternal mortality and morbidity. Bull World Health Organ. 2010 Jan;88(1):31–8.
- 15. Dandona R, Kumar GA, Henry NJ, Joshua V, Ramji S, Gupta SS, et al. Subnational mapping of under-5 and neonatal mortality trends in India: the Global Burden of Disease Study 2000–17. The Lancet. 2020 May 23;395(10237):1640–58.
- 16. Rapid Survey On Children (RSOC) 2013-14 | Ministry of Women & Child Development [Internet]. [cited 2022 Oct 29]. Available from: https://wcd.nic.in/acts/rapid-survey-children-rsoc-2013-14
- 17. Martin JA, Kochanek KD, Strobino DM, Guyer B, MacDorman MF. Annual summary of vital statistics--2003. Pediatrics. 2005 Mar;115(3):619–34.
- 18. S K, Kumar MS. Morbidity and mortality pattern of very low birth weight infants admitted in SNCU in a South Asian tertiary care centre. Int J Contemp Pediatr. 2018 Apr 20;5(3):720–5.
- 19. Mooorthi MMS, Nadesan B, Ramalingam E, Thirumalaikumarasamy S. A study of maternal factors influencing very low birth weight babies. Int J Contemp Pediatr. 2017 Jun 21;4(4):1173–8.
- 20. Durandy A. Ontogeny of the Immune System. Transfus Med Hemotherapy. 2003;30(5):222–7.

- 21. Mussi-Pinhata MM, Rego MAC. [Immunological peculiarities of extremely preterm infants: a challenge for the prevention of nosocomial sepsis]. J Pediatr (Rio J). 2005 Mar;81(1 Suppl):S59-68.
- 22. Melville JM, Moss TJM. The immune consequences of preterm birth. Front Neurosci. 2013;7:79.
- 23. Sampah MES, Hackam DJ. Dysregulated Mucosal Immunity and Associated Pathogeneses in Preterm Neonates. Front Immunol. 2020;11:899.
- 24. Carr R, Huizinga TW. Low soluble FcRIII receptor demonstrates reduced neutrophil reserves in preterm neonates. Arch Dis Child Fetal Neonatal Ed. 2000 Sep;83(2):F160.
- 25. van den Berg JP, Westerbeek EAM, Berbers GAM, van Gageldonk PGM, van der Klis FRM, van Elburg RM. Transplacental transport of IgG antibodies specific for pertussis, diphtheria, tetanus, haemophilus influenzae type b, and Neisseria meningitidis serogroup C is lower in preterm compared with term infants. Pediatr Infect Dis J. 2010 Sep;29(9):801–5.
- 26. Stevens SM, Richardson DK, Gray JE, Goldmann DA, McCormick MC. Estimating neonatal mortality risk: an analysis of clinicians' judgments. Pediatrics. 1994 Jun;93(6 Pt 1):945–50.
- 27. CRIB (clinical risk index for babies), mortality, and impairment after neonatal intensive care. The Lancet. 1995 Apr 22;345(8956):1020–2.
- 28. Parry G, Tucker J, Tarnow-Mordi W, UK Neonatal Staffing Study Collaborative Group. CRIB II: an update of the clinical risk index for babies score. Lancet Lond Engl. 2003 May 24;361(9371):1789–91.
- 29. Richardson DK, Gray JE, McCormick MC, Workman K, Goldmann DA. Score for Neonatal Acute Physiology: a physiologic severity index for neonatal intensive care. Pediatrics. 1993 Mar;91(3):617–23.
- 30. Richardson DK, Phibbs CS, Gray JE, McCormick MC, Workman-Daniels K, Goldmann DA. Birth weight and illness severity: independent predictors of neonatal mortality. Pediatrics. 1993 May;91(5):969–75.
- 31. Richardson DK, Corcoran JD, Escobar GJ, Lee SK. SNAP-II and SNAPPE-II: Simplified newborn illness severity and mortality risk scores. J Pediatr. 2001 Jan;138(1):92–100.

- 32. Gray JE, Richardson DK, McCormick MC, Workman-Daniels K, Goldmann DA. Neonatal therapeutic intervention scoring system: a therapy-based severity-of-illness index. Pediatrics. 1992 Oct;90(4):561–7.
- 33. Field D, Manktelow B, Draper E. Bench marking and performance management in neonatal care: easier said than done! Arch Dis Child Fetal Neonatal Ed. 2002 Nov;87(3):F163–4.
- 34. Horbar JD, Onstad L, Wright E. Predicting mortality risk for infants weighing 501 to 1500 grams at birth: a National Institutes of Health Neonatal Research Network report. Crit Care Med. 1993 Jan;21(1):12–8.
- 35. Maier RF, Rey M, Metze BC, Obladen M. Comparison of mortality risk: a score for very low birthweight infants. Arch Dis Child Fetal Neonatal Ed. 1997 May;76(3):F146-150; discussion F150-151.
- 36. García H, Villegas-Silva R, Villanueva-García D, González-Cabello H, López-Padilla M, Fajardo-Gutiérrez A, et al. Validation of a prognostic index in the critically ill newborn. Rev Investig Clin Organo Hosp Enfermedades Nutr. 2000 Aug;52(4):406–14.
- 37. Zupancic JAF, Richardson DK, Horbar JD, Carpenter JH, Lee SK, Escobar GJ, et al. Revalidation of the Score for Neonatal Acute Physiology in the Vermont Oxford Network. Pediatrics. 2007 Jan;119(1):e156-163.
- 38. Signorini DF, Weir NU. Any variability in outcome comparisons adjusted for case mix must be accounted for. BMJ. 1999 Jan 9;318(7176):128.
- 39. Vardhelli V, Murki S, Tandur B, Saha B, Oleti TP, Deshabhotla S, et al. Comparison of CRIB-II with SNAPPE-II for predicting survival and morbidities before hospital discharge in neonates with gestation ≤ 32 weeks: a prospective multicentric observational study. Eur J Pediatr. 2022 Jul;181(7):2831–8.
- 40. Amiel-Tison C: Neurological evaluation of the maturity of newborn infants, Arch Dis Child 43:89, 1968.
- 41. Farr V, Mitchell RG, Neligan GA, and Parkin JM: The definition of some external characteristics used in the assessment of gestational age in the newborn infant, Dev Med Child Neurol 8:507, 1966.
- 42. Dubowitz LM, Dubowitz V, and Goldberg C: Clinical assessment of gestational age in the newborn infant, J PEDIATR 77:1, 1970.

- 43. J. L. Ballard, MD, J. C. Khoury, MSc, K, Wedig, MD, L. Wang, MD, B. L. Eilers-Walsman, MD, and R. Lipp, MD. New Ballard Score, expanded extremely premature infants 1991:119:417-423
- 44. Streeter GL. Weight, sitting height, head size, foot length, and menstrual age of the human embryo. Contributions to Embryology I920;11:143-70.
- 45. Hern WM. Correlation of fetal age and measurements between 10 and 26 weeks of gestation. Obstet Gyneeol 1984;63:26-32.
- 46. BLOOD GAS ANALYSIS. https://newbornwhocc.org/pdf/Blood-Gas-Book-workbook-2008.pdf Deorari, AIIMS 2008
- 47. American Academy of Pediatrics Committee on fetus and newborn .The Apgar Score *Pediatrics* (2015) 136 (4): 819–822.
- 48. Apgar V. A proposal for a new method of evaluation of the newborn infant. Curr Res Anest Anal. 1953;32(4):260–267
- 49. American Academy of Pediatrics and American Heart Association. Textbook of Neonatal Resuscitation. 6th ed. Elk Grove Village, IL: American Academy of Pediatrics and American Heart Association; 2011
- 50. American College of Obstetrics and Gynecology, Task Force on Neonatal Encephalopathy, American Academy of Pediatrics. Neonatal Encephalopathy and Neurologic Outcome. 2nd ed. Washington, DC: American College of Obstetricians and Gynecologists; 2014
- 51. Samir Gupta, Steven M. Donn, Assessment of neonatal perfusion, Seminars in Fetal and Neonatal Medicine, 101144,2020:25:5
- 52. V.M. Miall-Allen, L.S. de Vries, A.G. WhitelawMean arterial blood pressure and neonatal cerebral lesionsArch Dis Child, 62 (10) (1987), pp. 1068-1069
- 53. Cunningham S, Symon AG, Elton RA, Zhu C, McIntosh N. Intra-arterial blood pressure reference ranges, death and morbidity in very low birthweight infants during the first seven days of life. Early Hum Dev 1999; 56: 151-165
- 54. Dalili H, Farrokhzad N, Kavyani Z, Sahebi L, Habibelahi A, Ashrafzade M, Faridpur F, Mamak Shariat F. Determination of Predictive Power of CRIB-II and SNAPPE-II in Mortality Risk of Neonates with Low Gestational Age or Birth Weight Admitted to the

Neonatal Intensive Care Unit. Iranian Journal of Neonatology. 2020 Dec: 11(4). DOI: 10.22038/ijn.2020.42513.1704.

<u>ANNEXURE – I</u>

ETHICAL CLEARANCE CERTIFICATE



B.L.D.E. (DEEMED TO BE UNIVERSITY) Date-

(Declared vide notification No. F.9-37/2007-U.3 (A) Dated. 29-2-2008 of the MHRD, Government of India under Section 3 of the UGC Act, 1956) The Constituent College

SHRI. B. M. PATIL MEDICAL COLLEGE, HOSPITAL AND RESEARCH CENTRE

INSTITUTIONAL ETHICAL CLEARANCE CERTIFICATE

The Institutional ethical committee of this college met on 11-01-2021 at 11-00 am to scrutinize the synopsis of Postgraduate students of this college from Ethical Clearance point of view. After scrutiny the following original/corrected and revised version synopsis of the Thesis has been accorded Ethical Clearance

Title: Comparision of Predictive Power of CRIB-II and SNAPPE-II in Mortality risk of early pattern neonate and Very low birth weight admitted to the Neonatal Intensive Care Unit.

Name of PG student: Dr Anju.T, Department of Paediatrics

Name of Guide/Co-investigator: Dr M.M.Patil, Professor of Paediatrics

CHAIRMAN, IEC Institutional Ethical Committee B L D E (Deemed to be University) Shri B.M. Petil Saudical College,

VIJAYAPUR-633163 (Karnataka)

Following documents were placed before Ethical Committee for Scrutinization:

- 1. Copy of Synopsis / Research project
- 2. Copy of informed consent form
- 3. Any other relevant documents.

ANNEXURE-II

RESEARCH INFORMED CONSENT FORM

B.L.D.E. Deemed to be University

SHRI B.M. PATIL MEDICAL COLLEGE HOSPITAL AND RESEARCH CENTRE, VIJAYAPUR-586103

TITLE OF THE PROJECT : "Predictive Power of CRIB-II and SNAPPEII

in Mortality Risk of Early Preterm Neonate

and/or Low Birth Weight"

"

GUIDE : Dr M M Patil MD

PROFESSOR, DEPARTMENT OF PAEDIATRICS

PG STUDENT: : Dr .ANJU T

PURPOSE OF RESEARCH:

I have been informed that the present study will help in screening for hearing loss in high risk neonates admitted to Shri B.M. Patil Medical College.

PROCEDUR E:

I understand that after having obtained a detailed clinical history, thorough clinical examination and relevant investigations, hearing screening will be done in high risk neonates.

RISK AND DISCOMFORTS:

I understand there is no risk involved and that the baby may experience some pain and discomforts during the examination. This is mainly the result of the condition and the procedures of this study are not expected to exaggerate these feelings which are associated with the usual course of treatment.

BENEFITS:

I understand that my participation in the study will have no direct benefit to me other than the potential benefit of the research and education.

CONFIDENTIALITY:

I understand that the medical information produced by this study will become a part of hospital records and will be subject to the confidentiality. Information of sensitive personal nature will not be part of the medical record, but will be stored in the investigations research file.

If the data are used for publication in the medical literature or for teaching purpose, no name will be used and other identifiers such as photographs will be used only with special written permission. I understand that I may see the photograph before giving the permission

REOUEST FOR MORE INFORMATION:

I understand that I may ask more questions about the study at any time;

Dr. ANJU T, at the department of Pediatrics is available to answer my questions or concerns. I understand that I will be informed of any significant new findings discovered during the course of the study, which might influence my continued participation. A copy of this consent form will be given to me to keep for careful reading.

REFUSAL FOR WITHDRAWAL OF PARTICIPATION:

I understand that my participation is voluntary and that I may refuse to participate or may withdraw consent and discontinue participation in the study at any time without prejudice. I also understand that Dr. ANJU T may terminate my participation in the study after she has explained the reasons for doing so.

INJURY STATEMENT:

I understand that in the unlikely event of injury to my baby resulting directly from baby's participation in this study, if such injury were reported promptly, the appropriate treatment would be available to the baby. But, no further compensation would be provided by the hospital. I understand that by my agreements to participate in this study and not waiving any of my legal rights.

I have explain	nedto the purp	pose of the research, the pr	ocedures required,
and the possible risks to	the best of my ability.		
Dr. ANJU T	-	Date	
(Investigator)			

PARENTS / GUARDIAN CONSENT STATEMENT:

We confirm that Dr.ANJU T is doing a study on "Predictive Power of CRIB-II and SNAPPE-II in Mortality Risk of Early Preterm Neonate and/or Low Birth Weight" a hospital based prospective observational study Dr ANJU T has explained to us the purpose of research and the study procedure. We are willing to give as much as information required for the study and consent for investigations and the possible discomforts as well as benefits. We have been explained all the above in detail in our own language and we understand the same

Therefore we agree to give consent for the baby's participation as a subject in this research project.

Date
 Date

Predictive Power of CRIB-II and SNAPPE-II in Mortality Risk of Early Preterm Neonate and/or Low Birth Weight

PROFORMA

1. Baby of:		
2. IP No:		
3. Date of Birth:		
4. Gestational Age:		
5. Time of birth:		
6. Classification:	AGA / SGA/ LGA	
7. Sex:		
8. Birth weight:		
9. Gravida:		
10. PIH:	YES	NO
11. GDM:	YES	NO
12. PROM:	YES	NO

13. Maternal Thrombocytopenia:	YE	S	NO	
14. Maternal Fever:	YES	NO		
15. Maternal H/O UTI:	YES	NO		
16. Chorioamnionitis:	YES	NO		
17. H/O Maternal vaginitis:	YES	NO		
18. MODE OF DELIVERY:	Nor	mal vaginal	/caesarean/forc	eps/vacuum
19. APGAR SCORE:	1m	in	5min	
Need for resuscitation IF YES	YI	ES :	NO	
20. NICU admission in hours:				
21. Primary Respiratory Support	: Nasal Pı	ongs/Hood	O2/CPAP/HFN	NC/SIMV
22. Clinical Sepsis:				
 a) Respiratory instability: apnea, tachypnea, increased o2 requirement/ Requirement for ventilation support: YES NO No of days on ventilator 				

b)	Cardiovascular instability: heart rate -
	urine output (<1ml/kg/hr.)-
	blood pressure (MAP)
	Capillary filling time
c)	Modified body temperature
d)	Gastrointestinal instability: feeding intolerance poor sucking abdominal Distension
e)	Skin and subcutaneous lesions: petechial rash or sclerema.
f)	CNS: irritability, lethargy, hypotonia, seizure.
04 5 1	
24. Early o	n Sepsis: a) Clinical Sepsis b) Probable Sepsis c) Proven Sepsis
23. ECHO	
23. ECHO	
26. Lab Pa	nrameter:
20. 24010	
a) V	White blood cells count
,	
c) P	latelet count
d) C	CRP
e) G	Blucose

f) Arterial Blood gas analysis
рН
pCO2
pO2
Нсо3
Metabolic acidosis with base excess (BE)
Serum lactate >2mMol/l
l) B lood Culture
27. Early onset sepsis YES NO
28. Early onset sepsis a) Clinical b) Probable c) Proven
27. Late onset sepsis YES NO
28. Late onset sepsis a) Clinical b) Probable c) Proven
29. Antibiotics received amongst below
a) Piptaz b) Amikacin c) Meropenam d) Vancomycin
d) Linezolid e) Colistin f) Amphotericin B
30. Culture positive in first 72 hours YES NO
If culture positive Organism

DIAGNOSIS

31. Need for inotrophic support	YES	NO	
If used: inotroph dopamine/adren	aline/nor adrenali	ne/sildenafil/milrinor	ie/
32. HIE	YES	NO	
33. HIE	Ι /	II / III	
34. Therapeutic Hypothermia	YES	NO	
35. Feeds intolerance	YES	NO	
36. NPO days			
37. Final outcome a) Discharged	b) Referred	c) DAMA d) Dea	th

CRIB SCORING

PARAMETERS	SCORE
Birth weight	
Gestational age	
Gender	
Base excess	
Temperature	

SNAPPE -II SCORE

Blood pressure (MAP) Temperature Serum ph PaO2/FiO2 Ratio Urine output	
(MAP) Temperature Serum ph PaO2/FiO2 Ratio	
Temperature Serum ph PaO2/FiO2 Ratio	
Serum ph PaO2/FiO2 Ratio	
Serum ph PaO2/FiO2 Ratio	
PaO2/FiO2 Ratio	
PaO2/FiO2 Ratio	
Urine output	
Urine output	
Seizures	
Weight	
Gestational age	
Five minute APGAR score	

Blogs Pin Dave of Blank Generation Age Generation Throat Giffen Sax Birth Weight specifies in Birth weight Classific Color Date Only Pin Color Pin	EP UD CRIG FPM Enters interrupts with C Relative Place(a) policy policy to hard interrupt and policy policy to hard interrupt policy policy because CS (Ear) One LOS Land Administration ME HET The Fact MID Find class MANDE CRISIC CRISIC LIGHT LIGH
Section Confession Confes	56 05 206 GOCO BUNNINGCLAR FUNCTION No. Advantage 2150 150000 Lasteman 5 126 273 225 115 00 11 123 123 No. Politic no. no. 16 Discharge 10 4 LUVIL (166) Discharge 14 LUVIL (167) Discharge 150 15000 College 150
Kaland jatego-poja 1812 7670201 33 30-1-34 70000AM Femina 1300.0 33 1051-91500 AA 3 1 1 No	27 6.5 M.1 0.000 BYNTHERULAR FUNCTION PM American 7700 26000 Learnard 97 14 50 140 40 07 70 12 12 Ave Closed No Paper No no no 10 Declarage 13 4 LEVEL 1(4)5.1 Declarage 13 4 LEVEL 1(4)5.1 Declarage 13 4 LEVEL 1(4)5.1 Declarage 14 10 10 10 10 10 10 10 10 10 10 10 10 10
VASSHALI SEA/ASENV 17507 0 2022201 34-4 34-5-1646 7:10:00 AM Francis 2000 3 4 2001 to 24:00 5 CA 1 YES No No NO NO No No No NORMA VASSHALL 6 8 2000 FM HODGO D Tachypenes Tachypenes 11010 0 7:00 NO	55 12 MAS GOCOD DIVENTACIONAR FUNCTION yns Dapartens 1346 15500 Lastelhans 76 74 152 252 40 81 4 14.3 No No Page No no 10 10 Statings 5 4 LEVEL 1 (40 Diventage 15 1 LEVEL 1 (40 Divent
Souther Section 19410 2020222 20west = 5 Days 20+-1 x 1.4550 DM Frame 19400 22 1001110500 AGA 2 2 1 1 No. No. VES. NO. NO. No. No. No. No. CASSAREAN 7 8 15009AM H00C0 D2 Tactypenes Tactypenes 174010 2140222 23 20-1-1 x 7.250-0.009M Miles 100. 00. 20 100110500 AGA 1 1 VES. No. No	22 1:1 25 PFO M85 yes Amenicalmic 1530 200000 40 53 74 264 55 20 65 28 57 No No Anishadon no no 20 Discharge 13 2 LUVEL (10-0) Gastrage 20 63 EST 190 No Anishadon No no yes 20 Guenty 25 2 LUVEL (10-0) Gastrage 20 63 EST 190 No Anishadon No no yes 20 Guenty 25 2 LUVEL (10-0) Gastrage 20 64 72 40 18 13 62 14 No Redailer No Anishadon No no yes 20 Guenty 25 2 LUVEL (10-0) Gastrage 20 64 72 40 18 13 62 14 No Redailer No Anishadon No no yes 20 Guenty 25 2 LUVEL (10-0) Gastrage 20 64 72 40 18 13 62 14 No Redailer No Anishadon No no yes 20 Guenty 25 2 LUVEL (10-0) Gastrage 20 64 72 40 18 13 62 14 No Redailer No Anishadon No no yes 20 Guenty 25 2 LUVEL (10-0) Gastrage 20 64 72 40 18 13 62 14 No Redailer No Anishadon No no yes 20 Guenty 25 2 LUVEL (10-0) Gastrage 20 64 72 40 18 13 62 14 No Redailer No Anishadon No no yes 20 Guenty 25 2 LUVEL (10-0) Gastrage 20 64 72 40 18 13 62 14 No Redailer No No yes 20 64 72 40 18 13 62 14 No Redailer No
Engine No. 17 (2014) 2012/22 2 201	34 68 34 GOODBINGTROUNT RUNCTION No others \$700 24000 (sumbset \$700 240 240 240 240 240 240 240 240 240 2
FOOL AS NOTED 2513 0 500020 5 100 5 20 5 20 1 100 0 0 M Female 4000 2 20 100 1 100 0 AGA 1 1 YES No No NO NO No No NO CASEAGRAN 5 7 20005PM SWY 3 Technyses Normal Reput SWY 25 No	2 1 2 2 3 3 5 5 5 5 5 5 5 5
1/20 1/20	36 0.8 34; FDA.A2D No ethers 13370 186000 52 80 730 522 88 45 16 22 87 ten Petados No Prata Pigazz No no no 48 Discharge 23 4 LEVEL [164] Discharge 10 0.00 187 0.00
250mm 14mm	22 c. 27 M-7 AGD MM2 yes Departmen 1999 250000 ft. 96 7.23 27.7 ft. 50 t. 28 11.6 No No Piper No no no 47 Descharge 1 2 6 LEVEL2[11-11-5] Descharge 2 1.1 LEA FOR PARTMEN NO
Gains 2222/2 1027/2021 2 22.50 1 22.50 1 22.50 1 22.50 1 22.50 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	50 69 32.5 PDA 10 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Streamen 24400 1182021 22 20-1-3 24102 M Set 100 M Sense 1800 2 20 1001 to 1500 AGA 8 No.	22 08 239 AED QUOD BINENTIFICIAR PAR Department 1989 250000 30 74 719 464 177 40 77 61 71 No. No. Reput No. no. no. 34 Deschaper 50 4 LEVEL (16-9) Deschaper 50 06 23.4 No. No. No. No. No. No. No. No. No. 24 Deschaper 50 4 LEVEL (16-9) Deschaper 50 06 23.4 No.
Admind Deceased G \$1500 \$252000 3 research (days \$20-1-36 \$125000 FM Female \$4600 \$3 \$100 ftm (200 \$4.2 \$1 \$1 \$1.0 \$10.0	34 08 347 PMC DAVE Electrical Policy PMC Department A053 380000 113 77 744 173 840 50 Hz 8 8 8 No. Hz PMC DAVE Electrical Policy PMC DAVE Electrical Policy PMC DAVE Electrical PMC DAVE E
BBLAN MASTER FAX 7844 581202 34-2 30-1-34 1440.0AM Femine 2000 3 200113249 AA 3 2 1 1 No No VES NO No No No ACESSEEAN 7 9 40000M MINORO OI Tatigness Normal Engineers are 1244 801200 34-2 34-344 20100 34 Femine 2000 3 200113249 AA No No No No NO VES NO ACESSEEAN 7 9 40000 MINORO OI Tatigness Normal Norm	26 03 36.4 FOA DOS DESTRUCTION FOR THE COLOR STRUCTURE FUNCTION FUNCT
Kemindak Human from 14416 4222022 3 Seekets 25-50 (19-20) 20 AM Mark 100.0 20 (100) 1450 (AM A 1 1 1 No	20 03 348 FOA-FFO-PM Moderane yet Administr 17120 207000 72 08 724 482 440 20 05 18 12 No. No. Aniskaft no no od Discharge 5 \$1.5747.2[4-0] Discharge 20 04 348 FOA-FFO-PM Moderane 300 10 10 10 10 10 10 10 10 10 10 10 10 1
Janua 13167 (1820222 20mass-featy 2b+-)-M 6:050 PM Male 1000 20 1007 s 1500 - 20 A ->-5 4 No No No No No No No No AGEAREAN 7 9 8:050 PM CPAP hossiest ougsers (Normal Mahad 132306 6:0500222 21 2b-1-4 12:050 PM CPAP hossiest ougsers (Normal Mahad 132306 6:0500222 2 1 2b-1-4 12:050 PM CPAP hossiest ougsers (Normal Mahad 132306 6:050 PM CPAP hossiest ougsers (Normal Mahad 132306 6:05	31 1.5 34.8 PFO yes Administr 7760 2003000 25 187 7.45 22.6 188 10 18 19 15 Yes Piezade No Ryanz Ariskado No no yes 50 Dictarge 15 6 LUNIZIO-10 Dictarge 20 1.75 34.0 PFO No. 10 18 19 18 19 18 19 19 19 19 19 19 19 19 19 19 19 19 19
Residenteegoods Add 1992 0f 1920222 32 304-1-34 125230 PM Framinis 1670 0 23 1550 1920 200 AGA 3 1 No	22 21 345 DA, FEO, PAPE Mid yet Admentials, 2820 254000 186 88 728 47.9 (164 80 20 15 22 19 2.7 Yet Polazales No. 19 19 19 19 19 19 19 19 19 19 19 19 19
Rouge Biomathemate (2000) 28/2007 25 25 26-1-24 72/200794 Fermin (2000) 25 25 (2000) 26/2007 25 25 (2000) 25/2007 25 (2000) 25/2007 25	34 O7 263 PFO, PM Mar yes Gugarina 1600 340000 5.5 157 245 237 117 30 15 31 0 No. No. Anniasin no. 0.3 Dicharge 2 4 LFVX. 1656 Dicharge 3 4 LFVX. 1656
Property of the Control of the Con	2 2 1 1 1 1 1 1 1 1
Remarks Mandard 2 11/1/2022 1054 2 20 20-1-3 8 13/20 20M Mark 100/20 20 20 20 20 20 20 20 20 20 20 20 20 2	33 08 328 PSA, PSA, ACD yet Doparties 7889 129000 72 88 732 385 58 30 20 61 5.5 No. No. Animalian yet 1 no no. 27 Discharge 2 4 4.5Vil. 1(50) Discharge 10 10 10 10 10 10 10 10 10 10 10 10 10
Broggarfreelanders 1556 4 415020 31-2 25-1-34 72200 MM Mar 1000 31 1001 1500 50 A 1 1 1 125 No 155 No 150 No No No No No NORMAK VAGGMAL 5 8 1300 AM CPAP Technorea Normal Steps Unservice 1750 2 20020 33-6 5 -1-34 8 41-000 MM Mar 1000 3 10101 1500 AM Service 1 1 1 1 125 No 155 No NO No No No CASEGORAN 7 8 1300 AM GRAV 3 Technorea Normal N	20 03 M3 PM, 605, CODO SYNTHEROULHE FINCT. yet Department 19270 197000 224 97 727 24 145 40 H1 3 13.3 No. No. Pigus, Artikano yet no. no. 27 Discharge 05 5 LEVEL 1(50) Discharge 10 17 30 H1 3 17 10 H1 2 H
Popu sadesty visite 11955 46/2022 34-1 54, 1-54-6 2105/MM Max 2006 34 2001 a 2409 AM 1 1 1 N N N N N N N N N N N N N N N N	22 03 361 1/06_0000 2000XTMTGULUAR FUNCTION yet Operation 7030 200000 64 88 744 221 137 20 15 4 18.3 Yet Obside Ne Affiliadin ne 50 20 Discharge 0 2 LEVEL 1 (1-0) 0 Discharge 1 0 Discharge 0 2 LEVEL 1 (1-0) 0 Discharge 1 DISCh
Regiment sealtheant 10415 4242022 3-7-2 261-34 200.00 FF finesh 200.00 20.00 FF finesh 200.00 FF finesh 200.00 20.00 FF finesh 200.00 FF finesh	20 1 24.4 PAL, Fall PAL
Separate Colonia Separate Co	1 2 2 2 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2
Anima starsfarmer 35/300 122/3007 30-6 - CB 1110/00/AM Fermins 7500.0 20 100/300 AM Fermins 7500.0 20 11 1 10 N N VES NO NO NA NA NA CASEAGEMEN 6 2 100/300 AM FERMINS NETHER STATES AND FERMINS NETHER STATES AM FERMINS NETHER STATES AND FERMINS NETHER STATES A	35 07 347 PM, PM, All Objection Francisco (400 year American S500 935000 22 500 195000 22 50 1950 27 10 10 17 10 17 10 17 10 17 12 50 74 1 10 10 10 10 10 10 10 10 10 10 10 10 1
Figure Numerations 2019 1 0112027 3-14 5 2-5364 2 20107 M Mark 2000 3 30 2010-2019 56.4 2 1 1 8 to 80 20 20 30 20 20 20 20 20 20 20 20 20 20 20 20 20	24 07 22.1 TOA, PED, PAN, VOG. GOOG BY/OTTFICED. yet. Adventables. 11-00. 200000 45 79 73 42 60 10 20 25 27 74 Clinical No. Ariesation. no. no. 22 Dearth 31 5 LEVEL 1(-0.0) Dearth 16 23.2 S 70 00 10 10 10 10 10 10 10 10 10 10 10 10
Martine part Mart	1
Proceedings Conference Co	20 ab 36.3 MTO yet Departmen 17200 250000 72 all 7.3 16.2 till 5 to 5.7 2 No No Page, Arthural, Margonium no no 22 Discharge 0 & LEVEZ_2[4-10] discharge 13 1 18.2 F.O.F.F.C.P.M.V.C.D. yet Departmen 4 2500 260000 240000 24 222 7.33 16.5 till 6 45 13 5 5 7.2 No Yet Public Page, Arthural, page no no 22 Discharge 0 2 LEVEZ_2[4-10] discharge 20 1 LEVEZ_2[4-10] discha
Single State Control of the Control	1
Proprieta Months 2000 12 (1992) 31-4-4-4-4-4-5 (1990) 41-4	34 04 32 270 No. Medicate 1536 27300 124 No. 272 224 43 120 46 92 27 7 Van Clerack No. Cinc. Paper No. no. no. 27 7 Chebrage 2 3 3 LVVX. (10-60 Darkstage 2 4 12 12 12 12 12 12 12 12 12 12 12 12 12
Nametria 11,500 \$77,507 30 mark 25 30 \$25,00 MM Mark 200.0 2 10,00 10,00 2 2 10,00 MM Mark 200.0 2 2 2 10,00 MM Mark 200.0 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	35 03 207 CO TO MAN MAR PRO 1800 1800 180 180 180 180 180 180 180 1
Pops Rempts 9:125 5142022 3114988 261-124 80000AM Male 14160 21 1051191500 AGA 1 1 1 125 NO	20 05 35 PFO MM2 No Administra 07720 200000 169 06 741 318 15 100 02 04 22 7 10 Clocal Ves Clock Anisoson No no yes 60 Referred 25 6 LSVL 2(1-6) Referred 25 0 06 313-05 (Clock Displaces) Proceedings 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Topics 1756 470000 20-5 1756 470000 20-5 1756	1
NameS Paser 8 0500 05223931 34 34,*534.6 11030 PM Femile 2230.0 34 20510.2400 AM Rels 210.0 34 20510.2400 AM Rels	34 S. 12.1 DOCO BUTCHTOOL Mat No enhers 10330 284600 5.4 82 732 32.7 78 40 0° 1.4 7 No No Royar No No Discharge 0 3 LVDVL 1(0)0 Discharge 1 0 1.0 LVDVL 1(0)
Alfabra Janesga 15345 9750021 20-05 25-35 5.000 PM Mark 100.0 25 1001 1500 AR 2 1 1 No No YES NO	20 0 3 25 PCO 98 Administra 700 247500 22 75 73 44 79 50 2 25 5 Ye Cloud No Pipus, Artistain No no no 45 Discharge 0 4 CUVIL-10-10 Discharge 20 15 3.57 PCO Pipus, Artistain No no no 45 Discharge 0 4 CUVIL-10-10 Discharge 20 15 3.57 PCO Pipus, Artistain No no no 45 Discharge 0 4 CUVIL-10-10 Discharge 20 15 3.57 PCO Pipus, Artistain No no no 45 Discharge 0 4 CUVIL-10-10 Discharge 20 15 3.57 PCO Pipus, Artistain No no no 45 Discharge 0 4 CUVIL-10-10 Discharge 20 15 3.57 PCO Pipus, Artistain No no no 45 Discharge 0 4 CUVIL-10-10 Discharge 20 15 3.57 PCO Pipus, Artistain No no no 45 Discharge 0 4 CUVIL-10-10 Discharge 20 15 3.57 PCO Pipus, Artistain No no no 45 Discharge 0 4 CUVIL-10-10 Discharge 20 15 3.57 PCO Pipus, Artistain No no no 45 Discharge 0 4 CUVIL-10-10 Discharge 20 15 3.57 PCO Pipus, Artistain No no no 45 Discharge 0 4 CUVIL-10-10 Discharge 20 15 3.57 PCO Pipus, Artistain No no no 45 Discharge 0 4 CUVIL-10-10 Discharge 20 15 3.57 PCO Pipus, Artistain No no no 45 Discharge 0 4 CUVIL-10-10 Discharge 20 15 3.57 PCO PIPUS NO
Pulgabania 17114 0 17021 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	2 0.5 26.7 PAN Male we contain the contained of the conta
Schaffersproading METP MICHAEL 2012/23 3-10 - 201-24 201	33 08 364 PRG PML CODE Midd No others 15202 2704000 3273 107 72 32 144 40 12 Ye Chroni No Paga, Astrono No no no 30 Discharge 13 4 LEVEL 1(10.0 Discharge 10.0 Discharge 10
Senirir 1 1820 474/2022 Mentar 2 days 34 + 5/44 10.00 0 MA Francis 2073 3 ± 001102440 207	55 07 35 PTG. GOOD DENTRECLIAR FUNCTION yet Advantage 13400 205000 317 79 278 276 122 89 60 25 6 No. No. Advantage representation of the Control of the Cont
Pubmersii	25 GB 251 MG GOOD DENTRECULAR FUNCTION yet Departmen 6765 220,000 6 70 7.3 262 82 30 46 2 82 74 Probable Yet Proba Articolo, Mergenes No. no. no. 32 Distribuye 8 4 LEVEL 1 (10.8) Distribuye 4 11 13.5 Probable Yet Proba Articolo, March 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Pubbers Indicated 2/72/20 1971/2029 124-52 1971/2029 1971/2029 124-5 204-1-24 4-4030/AM Made 1956 23 1509-2009 50A 2 1 1 175 No	34 07 36.2 PFO yet Administra 750 20000 7: 96 272 162 164 100 11 67 11 No Yet Clinc Piptra, Anistani, Mar No no no 20 Death 13 5 LVXVI.10(3) Death 13 63 36.2 PFO Anisani, Mar No no no 20 Death 13 5 LVXVI.10(3) Death 13 63 36 36 36.2 PFO Anisani, Mar No no no 20 Death 13 5 LVXVI.10(3) Death 13 63 36 36 36.2 PFO Anisani, Mar No no no 20 Death 13 5 LVXVI.10(3) Death 13 63 36 36 36 36 36 36 36 36 36 36 36 36
Amma makandar 20045 0742027 30+5 50-1-34 (0770978 Max 1050 20 120 120 120 120 120 120 120 120 120	31 15 35 9FO Mediente ynt Advantilles (1603) 119300 5 54 7.4 218 15 40 13 37 52 No. Clicard No. Clinic Pipize No. 1 no. yet. 25 Dicharges 77 4 LEVEX.2 (5-4-0) Dicharges 22 102.252 (97-0,000-0) STREAMPRINGTON yet. Dicharges 5 3 LEVEX.2 (5-4-0) Dicharges 7.5 10.0 Dicharges 7.5 10.
Second Column 1500 202391 1	20 07 257 PAS-PANG-DOOR Mide yet devination (4666 175000 72 95 725 151 162 66 45 72 17.6 No. No. Physic yet 16 yet 160 DAMA 20 51 11.0VEX.3[11-10] DAMA 20 51 15.0 163 163 163 163 163 163 163 163 163 163
Kelefram sealabolistic 11-1629 7/202021 52 50-1-34 17.20 2M Female 2020 24 201-10 201-	34 1.5 34.9 T/0.2 Policitarys 98 Administra 1000 215010 13.2 37.2 21.4 150 60 17.2 15 12.5 No. You Proba Polici Merogeneen No. no. 40 Distributys 2 4 LEVEL [1-0] Distributys 20 1.5 34.5 No. No. Policitarys No. no. 60 Distributys 2 4 LEVEL [1-0] Distributys No. no. 60 Distributys 2 4 LEVEL [1-0] Distributys No. no. 60 Distributys 2 4 LEVEL [1-0] Distributys No. no. 60 Distributys 2 4 LEVEL [1-0] Distributys No. no. 60 Distributys No. 60
Column 1/2/15 1	1 34 FOLY FOLY CONTRIBUTION OF THE PROPERTY OF
Analysis of 1972 (2007) 1 1973	2 1.5 2.6 3.4 Feb. (20.0 App.)
Sanguagement 17th 4:1702-25-114 200-25-114 2	20 (2) (3) (4) (4) (4) (4) (5) (5) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4
Tables argression 14870 F162020 22 25 - 1 2 25 -	23 03 35 750, 970, 794 Searce yes Admending 12500 175000 272 df 774 184 101 00 44 24 10.7 Van Printink Ne Amending yes 1 no no 34 Drawn 1 4 4 UVXL 1(50 Danth 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Exercise 15/10 1	50 07 56.1 FAM Maderate yes Admindist 700 240000 7.4 89 724 45 49 50 33 4.1 Yes Chould No Pipies No no so 38 DAMA 11 31 147VL 1(100 DAMA 21 22 22 22 22 22 22 22 22 22 22 22 22
Ashaba 4152027 22 23 23 25 36 650 0AM Female 8050 2 1000 500 AG 1 1 1 172 No	20 d 2-31 FFG, PAH, Epicar Ellate yet Administra 12000 172000 8.1 78 7.02 56 27 100 49 7.4 12.1 Yet Chroni No Ambasin no so 17 Death 31 10.1 CTG, 27 10 10 10 10 10 10 10 10 10 10 10 10 10
Streams SCRisson SCRIsson SCRISS 1972 1072/2021 34-1-2 34-1-364 127:50 PM Mas 100.0 34 1001 150.0 AA 1 1 1 YES NO	26 12 362 PG_0,000 DEVENTECLAR FUNCTION yet Adventure 6236 30160 133 75 725 362 134 60 15 28 27 Yes No. Page, Artistan No. no. no. 25 Discharge 8 4 LEVEL 1(50) Discharge 100 100 100 100 100 100 100 100 100 10
Bussers growins 251746 (14/0202) 21/5 (26/1-14) 2,200.00FM Mass 1700.00 22.00fm 2500 20.00	1
March Marc	20 03 54 FFG GOOD SEVENTECULAR FUNCTION yet Administr (433) 20160 65 55 754 21 27 42 14 15 16 No. No. Administration No. No. No. No. No. 12 Districtory 9 3 LEVEL (1962 Discharge 10 12 No. No. Administration No. No. 12 Districtory 9 2 LEVEL (1962 Discharge 10 12 No. No. Administration No. No. 12 Districtory 9 2 LEVEL (1962 Discharge 10 12 No. No. Administration No. No. 12 Districtory 9 2 LEVEL (1962 Discharge 10 12 No. No. Administration No. No. 12 Districtory 9 2 LEVEL (1962 Discharge 10 No.
Strait Rate Strains 2505 42222291 22 25 25 25 20 20 28 1 Mark 1500 25 1691 ts 100 25 25 25 25 25 25 25 25 25 25 25 25 25	30 03 348 0000 BVENTECULAR PLANCING MR. Aprillation 14410 24000 Linearmes 60 6.70 258 74 150 24 12 216 No. No. Pigus. No. no. yet 100 DMA. 27 3 LUVEZ 16-10 DMA. 3 14 15 216 No. No. Pigus. Askinson No. no. of 60 Districtory 25 6 LUVEZ 16-10 DMA. 3 14 15 216 No. No. Pigus. Askinson No. no. of 60 Districtory 25 6 LUVEZ 16-10 DMA. 3 14 No. No. Pigus. Askinson No. no. of 60 Districtory 25 6 LUVEZ 16-10 DMA. 3 14 No. No. Pigus. Askinson No. no. of 60 Districtory 25 6 LUVEZ 16-10 DMA. 3 14 No. No. Pigus. Askinson No. no. of 60 Districtory 25 6 LUVEZ 16-10 DMA. 3 14 No. No. Pigus. Askinson No. no. of 60 Districtory 25 6 LUVEZ 16-10 DMA. 3 14 No. No. Pigus. Askinson No. no. of 60 Districtory 25 6 LUVEZ 16-10 DMA. 3 14 No. No. Pigus. Askinson No. no. of 60 Districtory 25 6 LUVEZ 16-10 DMA. 3 14 No. No. Pigus. Askinson No. no. of 60 Districtory 25 6 LUVEZ 16-10 DMA. 3 14 No. No. Pigus. Askinson No. no. of 60 Districtory 25 6 LUVEZ 16-10 DMA. 3 14 No. No. Pigus. Askinson No. no. of 60 Districtory 25 6 LUVEZ 16-10 DMA. 3 14 No. No. Pigus. Askinson No. no. of 60 Districtory 25 6 LUVEZ 16-10 DMA. 3 14 No. No. Pigus. Askinson No. no. of 60 Districtory 25 6 LUVEZ 16-10 DMA. 3 14 No. No. Pigus. Askinson No. no. of 60 Districtory 25 6 LUVEZ 16-10 DMA. 3 14 No. No. Pigus. Askinson No. no. of 60 Districtory 25 6 LUVEZ 16-10 DMA. 3 14 No. No. Pigus. Askinson No. no. of 60 Districtory 25 6 LUVEZ 16-10 DMA. 3 14 No. No. Pigus. Askinson No. no. of 60 Districtory 25 6 LUVEZ 16-10 DMA. 3 14 No. No. Pigus. Askinson No. no. of 60 Districtory 25 6 LUVEZ 16-10 DMA. 3 14 No. No. Pigus. Askinson No. no. of 60 Districtory 25 6 LUVEZ 16-10 DMA. 3 14 No. No. Pigus. Askinson No. no. of 60 Districtory 25 6 LUVEZ 16-10 DMA. 3 14 No. No. Pigus. Askinson No. no. of 60 DMA. 3 14 No. No. No. Pigus. Askinson No. no. of 60 DMA. 3 14 No. No. No. Pigus. Askinson No. no. of 60 DMA. 3 14 No. No. No. Pigus. Askinson No. no. of 60 DMA. 3 14 No. No. No. Pigus. Askinson No.
Engagement Miles 1922-2017 201-1 201-1 1922-2017 201-1 1922-2017 201-1 1922-2017 201-1 1922-2017 201-1 1922-2017 201-1	23 18 347 PM 450 M86 yes Administra 8079 64000 42 60 732 32 786 32 18 2 18 18 19 19 19 19 19 19 19 19 19 19 19 19 19
Exercised 1328 420/2027 52 52 55 110/2020 AM Mars 160/5 23 16/111 16/202 AM Mars 160/5 23 16/11 16/202 AM Mars 160/5 23	34 1 264 790,4 PML AND Mod yet Admendian 6570 150000 18 NJ 74 26 127 60 16 28 7.5 Yes Principles New Pages No. no. no. 55 Discharge 8 7 LEVEZ 3/1-10 Discharge 12 11.2 26 000 WINTERDELOUP FUNCTION yet Admendian 6570 15000 14 NJ 74 26 127 60 16 28 7.5 Yes Principles No. no. no. no. 55 Discharge 8 7 LEVEZ 3/1-10 Discharge 12 11.2 26 000 WINTERDELOUP FUNCTION yet Admendian 6570 15000 1500 1500 1500 150 16 22 7 12 NJ 75 No. no. no. no. 10 Discharge 12 NJ 10 DISCharge 12
Second	54 1.4 36 COOS DEVENTIONLAND FUNCTION. He other 9506 87000 x 5 10 7.4 224 100 40 18 4 75 No. No. Paper No. no. to 24 Dataseps 0 4 LEVEL (160 Dataseps 1 1 1 A 25 No. No. Paper No. No. to 24 Dataseps 0 4 LEVEL (160 Dataseps 1 1 1 A 25 No. No. Paper No. No. to 24 Dataseps 0 4 LEVEL (160 Dataseps 1 1 1 A 25 No. No. Paper No. No. to 24 Dataseps 0 4 LEVEL (160 Dataseps 1 1 1 A 25 No. No. Paper No. No. to 24 Dataseps 0 4 LEVEL (160 Dataseps 1 1 1 A 25 No. No. Paper No. No. to 24 Dataseps 0 4 LEVEL (160 Dataseps 1 1 1 A 25 No. No. Paper No. No. to 24 Dataseps 0 4 LEVEL (160 Dataseps 1 1 1 A 25 No. No. Paper No. No. to 24 Dataseps 0 4 LEVEL (160 Dataseps 1 1 1 A 25 No. No. Paper No. No. to 24 Dataseps 0 4 LEVEL (160 Dataseps 1 1 1 1 A 25 No. No. Paper No. No. to 24 Dataseps 0 4 LEVEL (160 Dataseps 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
pigmbre export 5207 2522221 23 20-1-31 52500 AM Mas 100.0 23 1509-1200 AM A 2 2 1 No YES No NO No No No No CAESAREAN 8 9 10000 AM 1000 CO 2 Apensa Normal Animal Recommendary part 7541 8 6,0000 3 20 3 2 2 2 2 2 2 2 2 2 2 2 2 2 2	23 20 35 PM MM yes Administra 500 100000 12 10 72 10 102 of 10 1 1. No. Cloud No. Cloic Figura: yes 1 no. no. 16 Distribuye 8 8 LEVEL3(11-16) Cinclemps 1 1 2. The Cloud No. Cloic Figura: he no. no. 16 Distribuye 9 8 LEVEL3(11-16) Cinclemps 1 1 2. The Cloud No. Cloic Figura: he no. no. 16 Distribuye 3 1 CENTRAL 11-16 Cinclemps 1 2 CENTRAL 11-16 Cinclemps 1 2 CENTRAL 11-16 CINCLEMPS 1 CENTRAL 11-16 CINCLEMP
Width & Damage and 5137 GY22021 31 50-1-38 82.00 AM Mark 1700 31 1500 9200 500 4 4 4 No No NO No No NO CAESAREAN 9 9 20000 M mere 2 pages No	22 100 28 PAH MMd yes Dopasteria 200 100000 8 120 721 22.4 400 50 6 13 8.3 No. Olived No. Clinic Amplicación Merigines No. 8 no. 70 25 Dictorage 8 9 LEVEL 2(1-4-10) Dictorage 1 100 28 PDA MMd No. Dopasterianis 500 000000 120 120 724 127 170 50 15 42 No. Clinical Yes Chica Amblican Merigines No. 8 no. no. 25 Dictorage 7 8 LEVEL 2(1-4-10) Dictorage 2 No. 100 200 200 200 200 200 200 200 200 200
Administration 20051 (2002051 54 50-1-4 20020FM Female 1752 54 1500-200 AA 2 1 1 No	34 07 25.1 PGQ-PAIM Mail yet Dogarinin 4500 14450 154 78 721 46.6 191 60 25 11 32 Vet Cloud No Pingu, Artistato yet 1 no no 46 Distanting 1 3 LEVEL [160] Distanting 1 3 12 Mail Review No no yet 20 Distanting 1 3 LEVEL [160] Distanting No no yet 20 Distanting 1 3 LEVEL [160] Distanting No no yet 20 Distanting 1 4 LEVEL [160] Distanting No no yet 20 Distanting 1 4 LEVEL [160] Distanting No no yet 20 Distanting 1 4 LEVEL [160] Distanting No no yet 20 Distanting 1 4 LEVEL [160] Distanting No no yet 20 Distanting 1 4 LEVEL [160] Distanting No no yet 20 Distanting 1 4 LEVEL [160] Distanting No no yet 20 Distanting 1 4 LEVEL [160] Distanting No no yet 20 Distanting 1 4 LEVEL [160] Distanting No no yet 20 Distanting 1 4 LEVEL [160] Distanting No no yet 20 Distanting 1 4 LEVEL [160] Distanting No no yet 20 Distanting 1 4 LEVEL [160] Distanting No no yet 20 Distanting 1 4 LEVEL [160] Distanting No no yet 20 Distanting 1 4 LEVEL [160] Distanting No no yet 20 Distanting
Part	1 1 1 1 1 1 1 1 1 1

Summa Control waterward 20 29-20 19000004 Femines 12000 29 20 10010004 Femines 12000 29 20 100100004 Femines 12000 20 20 100100004 Femines 12000 20 20 20 10010004 Femines 12000 20 20 20 20 20 20 20 20 20 20 20 20	24 Chair Annie 24 Chair Annie 25 Cha
Changers 15000 15000 13-7 15-7 15	33 13 34 FMA Mid: ppt Abministre 1377 55500 167 89 737 123 11 60 53 127 17.4 No. Pipter 15 10 10 10 10 10 10 10 10 10 10 10 10 10
Second 1975	Part
Advantamentari 1922 77/2027 27-2 27-2 27-2 27-2 27-2 27-2 27-2	24 07 24.4 PTO yes Amendmen 900 100000 5 120 725 231 114 00 18 15 15 14 No. 10 Paper, Amendmen No. 10 Table 11 12 14 Table 11 15 15 15 15 15 15 15 15 15 15 15 15
	20 12 36 TRA PTO GOOD SWINTERCOLLET FULL part American 1500 220000 176 42 7-0 16:5 104 50 10 17 12 7-0 16:0 Full Part American 10-0 Full Part American
	State
Abasa 25066 [020232] 20 20-1-34 [1-050-040 Mark [02] 20 1001-1000 AAA 1 1 50 10 50 50 50 50	20 03 24 PA. PA. 948 Dicharderie (1602 1900) 5 69 74 21 53 60 13 17 6 74 60 1004 74 9145 Pagas, Arbaican No. no no 55 Dicharder 8 5 LVPC1 (10-55 Dicharder) 10 20 12 15 15 97 60 1004 74 9146 7166 7166 7166 7166 7166 7166 7166 7

	1
Notation 1972 02:002:1 22:00 12:0007 02:00 22:00 12:0007 02:00 22:00 12:0007 02:00 12:0007 02:	7 \$ 1000840 CRFP Trainprise Normal 34 \$1.110 ps American 1889 50500 1 \$ 1 \$1.71.2124 108 815 15 \$1.21 to Touce 16 Figure 15 no. 16 \$2.00000 20 \$1.00000 109 \$1.000000 109 \$1.000000 109 \$1.00000 109 \$1.00000 109 \$1.00000 109 \$1.00000 109 \$1.00000 109 \$1.00000 109 \$1.00000 109 \$1.00000 109 \$1.00000 109 \$1.00000 109 \$1.000000 109 \$1.00000 109 \$1.000000 109 \$1.000000 109
Lawri ganesh maith 195893 376/13722 23+1 35-1-34 50:00:00 MM Mais 220:00 23 400 3499 AGA 2 1 Ne No No NO NO No Ne Ne CASSAREAN 1 676/391201 31 34-3-5-4-58 20:00:00 PM Firmitie 10:00:00 31 12010 3200 AGA 1 Ne No	7 9 123000AM CPAP Tachypres Bradycards (32 0.9 36.1 FDA, PFO, PM Mid yes Adminishe 179201 1780000 172 102 7.48 31.6 182 20 13 22 14 Yes Clinical Yes Proba Piptar No no no 46 Clinical Yes Proba Piptar
6/29/2021 31 24-5-34-6 2006/0 F Female 1600.0 31 1500 1200 AGA 1 No No NO NO NO NO NO NO NORNAL VAGINAL 7 Supramadevi 28804 12/9/2021 33-5 26-1-34 2000 AM Marie 2000.0 21 1500 1200 AGA 1 1 No	7 5 1 202000 M CPAP Tanipura Bangarati 22 6 3 34 TR, TAT, TAT, TAT, TAT, TAT, TAT, TAT,
Needland 1977ak \$2522291	7 5 1 20000M CPAP Templeme Bougarded 1 2 6 3 34 TO, NG 70 M Me 1 44 American 1021 10000 121 76 15 16 1000 121 76 15 16 1000 121 76 15 16 1000 121 76 15 16 1000 121 76 15 16 1000 121 76 15 16 1000 121 76 15 16 1000 121 76 15 16 1000 121 76 15 16 1000 121 76 16 16 16 16 16 16 16 16 16 16 16 16 16
Supriya transmulsas 177589 525/2022 21+2 20+1-34 3:500.00 M Marie 140.0 21 1001 to 1500 AGA 1 1 1 No No YES NO NO No No No NORMAK YAGNNAL 6 Kwwtip traven kaide 18275 5105/2002 34 34-5-36+6 600.00 M Female 1703.0 34 1050 1200 AGA 2 2 No NO NO NO NO NO NO NORMAK YAGNNAL 75 NORMAK YAG	6 7 100003M SMV 2 Increased congregative Normal 2 2 23 25.8 FOA. FFO yes Advanction 1500 2500009 16 6 75.0 25.0 19.0 19.0 19.0 19.0 19.0 19.0 19.0 19
Tell polytest remains 2004 207/2012 2 201-1 2 200/2014 200 200/2014 200/20	5 7 19505MH 2007 2 Terminating growth formul 12 2 32 56 19 KPG 7 1 19 19 19 19 19 19 19 19 19 19 19 19 1
Fig. 1 (2012) 1 (2012	1 1 1 1 1 1 1 1 1 1
Same Paradiag Sandar 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	7 9 - 2000-05AM HIFFIC Tachippeas Normal 24 68 26 PFG,QCOD BillerSTRDCUMF 1902 Departments 12500 1250009 66 79 7.27 22.5 117 60 12 22 154 Vac Clinical No Parkinskin No no no 46 Distance 5 4 LUVEL (1)6-0 Distance 7 9 1500-05AM SISTEV 3 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Girlis Entersyst wording 277097 121/12021 34 30+1-34 648:00 AM Marie 1900.0 34 1500 to 2000 AGA 3 2 2 No	7 \$ 1000 MB 2000 7 Tanjungan Norma 22 6 3 32 370 ANA 0.000 00 H Information 400 2000 6 7 10 27 20 11 10 10 10 1 1 10 10 10 10 10 10 10 1
Suminar Prabha Pass 10015 4020021 34 34.+-584-6 8:52:00 AM Femals 2000.0 34 2001 to 2409 AGA 1 No No YES NO NO No No NO MCRIMAL VAGINAL 6 State System 1 1000 AGA 1 No No YES NO NO NO No No NO AGA 3 2 2 YES YES NO NO NO NO NO AGA 3 AGA 1 NO NO YES NO NO NO NO NO AGA 3 AGA 1 NO NO YES NO NO NO NO NO AGA 3 AGA 1 NO NO YES NO NO NO NO NO MCRIMAL VAGINAL 6 Suminar Parababa 10015 4 200001 AGA 3 AGA 1 NO NO YES NO NO NO NO NO MCRIMAL VAGINAL 6 AGA 1 NO NO YES NO NO NO NO NO MCRIMAL VAGINAL 6 AGA 1 NO NO YES NO NO NO NO NO MCRIMAL VAGINAL 6 AGA 1 NO NO YES NO NO NO NO NO MCRIMAL VAGINAL 6 AGA 1 NO NO YES NO NO NO NO NO MCRIMAL VAGINAL 6 AGA 1 NO NO YES NO NO NO NO NO MCRIMAL VAGINAL 6 AGA 1 NO NO YES NO NO NO NO NO MCRIMAL VAGINAL 6 AGA 1 NO NO YES NO NO NO NO NO MCRIMAL VAGINAL 6 AGA 1 NO NO YES NO NO NO NO NO MCRIMAL VAGINAL 6 AGA 1 NO NO YES NO NO NO NO NO MCRIMAL VAGINAL 6 AGA 1 NO NO YES NO NO NO NO NO MCRIMAL VAGINAL 6 AGA 1 NO NO YES NO NO NO NO NO MCRIMAL VAGINAL 6 AGA 1 NO NO YES NO NO NO NO NO MCRIMAL VAGINAL 6 AGA 1 NO NO YES NO NO NO NO NO MCRIMAL VAGINAL 6 AGA 1 NO NO YES NO NO NO NO NO MCRIMAL VAGINAL 6 AGA 1 NO NO YES NO NO NO NO NO MCRIMAL VAGINAL 6 AGA 1 NO NO YES NO NO NO NO NO MCRIMAL VAGINAL 6 AGA 1 NO NO YES NO NO NO NO NO MCRIMAL VAGINAL 6 AGA 1 NO NO YES NO NO NO NO NO MCRIMAL VAGINAL 6 AGA 1 NO NO YES NO NO NO NO NO NO MCRIMAL VAGINAL 6 AGA 1 NO NO YES NO	\$ 1 \$2500.04 (000.000) Tailgrand Temperals 26 \$ 21 \$24 50.0 \$ 10 \$100.000 \$ 100.000 \$
	2 2 2 2 2 2 2 2 2 2
Rajastree Roli 100752 7/15/2021 20+5 30+1-34 12:27:00 PM Female 200.0 33 2001 to 2469 AGA 3 2 2 No No No No No No No No CAESAREAN 7	7 9 :127:07PM CPAP Tachigensa Normal 34 :13 32.8 PTO yes Advancian 30500 200000 Less team 5 To 7.4 : 108 :114 :40 :16 :57 :5.8 No No Refer No no do Dictionaria 0 4 :10 20.8 PCP No Refer No no No Dictionary 0 4 :107.1 (1)40 Dictionary 1 4 :107.1 (1)40 Dic
Summinan rough 1727 WR0217 247 2 204-1-4 1700078M 1820 1000 2 2050 200 AGA 1 No No NO NO NO NO NO CARLAGAM 1 No	7 1 1 1 1 1 1 1 1 1
Septimental 1: 1266 4 (1202011 Messale Sept. 1266 4 (1202019 Messa	7 5 25000FN PM P TOURISM NEW P
ashinin 214-014 10014/2021 34 weeks 543 ys 34,+5454 32:00:00 PM Male 2000 34 000 11500 12:000 AGA 1 No No YES NO NO No No NO RORBALL VAGINAL B Appara 26 vorg stabs 11915/2021 77/2020 21 34 weeks 143 ys 34,+5464 62:00 20 20 20 20 20 20 20 20 20 20 20 20 2	1 2 2 2 2 2 2 2 2 2
Application of the Control of the Co	7 \$ \$ \$200,00M serVer. Techniques Novelet 31 \$12 POS-NFO-76-18 state \$600 \$22000 \$15.5 \$6.7 \$22.5 \$18.4 \$16.5 \$72.5 \$18.5 \$10.
Surjay Chromotheria 198224 ST170022 23 34 -1-36-6 S0-620 PM Male 21300 32 2001 to 2469 AGA 1 YES No. NO. YES No. NO. YES No. NO. NO. NORMAL VAGINAL 7 Special Patrick State of the Control	7 \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$
April	2 2 2 2 2 2 2 2 2 2
	7 8 1/100/2014 (1/100/100 1 1/100/100 1 1/100/100 1 1/100/100
Animal Structure are 18448 9199001 50-5 28-50 52000 FM Main 15000 25 1001 1500 AGA 2 1 1 No No YES NO NO No No No AGASAGAN **Manual Structure 18448 9199001 50-5 28-50 52000 FM Main 15000 25 1001 1500 AGA 2 1 1 No No YES NO NO No No No AGASAGAN **Animal Structure 18448 9199001 50-5 20 1001 1500 AGA 2 1 1 No No YES NO	7 8 55000 M HINFIG Tadigenes Normal 35 61 251 ADD, COORDINATECULAR FUNCTION yet Delatements 2700 22000 6 70 7.3 322 61 00 16 3 22 Yet Peables Yet Peab Anhabed, Neuropse Normal 30 60 M 67 PG COORDINATECULAR FUNCTION yet Delatements 2700 22000 6 70 7.3 322 61 00 16 3 22 Yet Peables Yet Peab Anhabed, Neuropse Normal 30 60 M 67 PG COORDINATECULAR FUNCTION yet Delatements 2700 22000 6 70 7.3 322 61 00 16 3 22 Yet Peables Yet Peab Anhabed, Neuropse Normal 30 60 M 67 PG COORDINATECULAR FUNCTION yet Delatements 2700 22000 6 70 7.3 322 61 00 16 3 22 Yet Peables Yet Peab Anhabed, Neuropse Normal 30 60 M 67 PG COORDINATECULAR FUNCTION yet Delatements 2700 22000 6 70 7.3 322 61 00 16 3 22 Yet Peables Yet Peab Anhabed, Neuropse Normal 30 60 M 67 PG COORDINATECULAR FUNCTION yet Delatements 2700 22000 6 70 7.3 4173 70 7.3 4173 70 7.3 52 Yet Delatement 2700 PG PG COORDINATECULAR FUNCTION YET DELATEMENT AND YE
Mammanig markhoode 85/92 922/2020 324 + 34 + 546-6 400/00 PM Marke 700.0 23 1500 102000 AGA 1 No ACESAREAN 3 Malama bitimarayan 12820 422/2020 334 + 34 + 546-6 24000 AM Marke 2500.0 23 25 AGA 2 No ACESAREAN 3 Sunitar 15000 500/2022 24 2500/202 2500/2020 26 26 26 26 26 26 26	7 8 5666/09 (CSAP Tantipassa Narmal 36 07 567 PAN, GOOD DUNCT Mids 100 class has 5 07 567 PAN, GOOD DUNCT Mids 100 class has 5 07 567 PAN, GOOD DUNCT Mids 100 class has 5 07 567 PAN, GOOD DUNCT Mids 100 class has 5 07 567 PAN, GOOD DUNCT Mids 100 class has 5 07 567 PAN, GOOD DUNCT Mids 100 class has 5 07 567 PAN, GOOD DUNCT Mids 100 class has 5 07 567 PAN, GOOD DUNCT Mids 100 class has 5 07 567 PAN, GOOD DUNCT Mids 100 class has 5 07 567 PAN, GOOD DUNCT Mids 100 class has 5 07 567 PAN, GOOD DUNCT MID 100 class has 5 07 567 PAN, GOOD DU
Teacher Column	7 2 \$2.000 M 1.000 M
Sawka pojesi 287986 128/2021 22:304-1-34 6:00:00 PM Maile 1150 22 10011e1500 AGA 1 YES NO YES NO NO NO NO NO AKESAREAN 6 Shahii jalagar 1071-10 71:2021 20:24-10 22:00 PM Maile 4:00.0 20 10011-1050 LGA 1 NO	6 8 7-00-00/99 HiPFINC Tachyponas Normal 30 t.1 15.5 PFC yes Adexenites 19050 172400 122 76 7.35 23.2 93 40 13 5.3 11.7 No Pechalis No Poda Piptar, Arisació No no yes 72 Distratege 13 6 EUVEL (1-6) Discharge 6 8 115.00-00/99 HiPFINC Tachyponas Normal 30 45 35.4 PFC yes Adexenites 7460 150000 17 65 7.244 460 140 40 21 4 30 Normal 75 10 10 10 10 10 10 10 10 10 10 10 10 10
bds mukeuk heakhar 26/1972 4/192021 31-5 34,-1546-6 104600 MM Female 15000 31 101/101/101/50 SGA 2 1 YES No. NO. NO. NO. NO. NO. NO. ACEARAGEN 3 North-Public Public Publi	7 9 115200PM CPAP Tachypnasa Normail 36 68 254 PM4,455,GCOC BYUNTRICULUR FANC yes Adendaline 7910 200000 116 58 72 28.3 152 50 17 28 6.5 No Pobable No Poba Pigura, Avisado no yes 60 Dictorage 5 5 LEVEL (1-6) Dictorage 1 8 1 LEVEL (1-6) Dictorage 1 REVISION (1-6) DICTORAGE 1 REVI
Post Indicated Headings and Letter 40 m 200 m	7 5 1 1500/09 (CPAP Tempera Normal 36 8 35 FM, AGA, QCO, SPACTER CLAFF FMC yet Abmenda 97:10 20000 114 52 3 23 23 11 12 50 7 23 5 16 Pm Andrew Parks PML
Section Control Cont	1
Revision thrombal mass 164443 32902021 34 34 -1-1646 7 2200 DM Femmins 2300.0 34 0501 10 2469 MGR 2 1 No No NO NO NO NO NO CAESAREAN 1 Milliamma Nationaliza 23200 11 11 11 11 11 11 11 11 11 11 11 11 1	7 8 1 2005/07 00 70 70 1 2005/07 00 70 70 70 70 70 70 70 70 70 70 70 7
Malamme Newarata 28700 191/2009 35-6 54-1-9344 73200 PM Male 18000 53 1500 10200 AGA 1 YES No NO NO NO NO NO NO NO NO AGASEAN 1 General Section 1 1 NO	8 W EXTRAORM CVAP 1 EXTRAORM SWITH 3 34 W 2A PS (LOCAD WINNINGCLIAN FORCH INN 9K Administra 1910 20400 51 42 72 23 810 20 13 184 72 10 1000 52 14 NO CHICAR Y AC CHICA WARA (Antiques no 50 02 20 WINNINGCLIAN FORCH INN 9K Administra 19210 314000 52 47 78 78 24 15 16 70 50 52 14 NO PROBLEM FORCE NO 50 50 20 WINNINGCLIAN FORCE NO 50 20 WINNINGCLIAN FORCE NO 50 20 WINNINGCLIAN FORCE NO 50 50 WINNINGCLIAN FORCE NO 50 50 WINNINGCLIAN FORCE NO 50 WINNINGCLIAN FORCE N
General patient reg. 16479 2002007 20-1 34-15-064 1180/07N Femile 20000 3 15001-02000 AM 1 175 No No YES NO No No NO NO NO NO NO CASSAGEN 3 1 No	6 8 4 425094M MODGO 2 Tachpress Normal 20 1.3 26.8 FG yes Assembles 4152 21500 7 7 79.739 29.2 151 61 67 Yes Clinical No Proba Piptur yes 1 no no 22 Discharge 8 3 LUVEL1(96) Tachpres Normal 20 1.3 27 VEG. AND yes Copporing A 100 100 100 100 100 100 100 100 100 1
Part	6 1 10 10 10 10 10 10 10
Jeptis rancer 120687 755:0021 20 20 30 10:00:00 PM Female 10:00 20 1:00:10:050 AGA 1 No No NO NO YE No No NORMAL VAGRALL VAGRAL VAGRAL VAGRALL VAGRALL VAGRALL VAGRALL	6 8 200:00 PM HMFINC Tachgarea Normal 20 072 345 FDA. A denotative 1000 200:000 57 75 745 226 14 20 15 4.9 8 No Pockadir No Pricks Rights No no no 20 Discharge 13 8 LEVEL (16-10 Discharge 5 LEVEL
SRUSHTI CHARRAY \$5390 \$47202001 23 34.+34-56 \$6200 PM Female 20080 23 1509 10:2000 AGA 1 No No NO YES NO NO No No No CAESAREAN 1 LANGSPRIGHAEL 158400 \$2240201 34.4 34.+34-64 \$11200 20 AM Female 20000 3 1509 10:2000 AGA 1 No	8 9 10-02-007M HODDO 27 Tachigenes Normal 36 0.7 36 FDA.PAH Seere yet Dispension A 154400 234000 237 78 74.1 26.5 T14 40 98 1.5 4.5 Yet Clinical No. Clinic Piptar, Antherisch No. no no. 48 Discharge 9 3 LEVEL 1(4-0) Discharge 9 10-02-007M CAPAT Tachigenes Normal 36 0.0 36.4 MFD, Replaced Fraction-1-0-0-0, Wet Dispension 0-10 10 170000 34 10 78 Tachigenes Normal 36 0.0 36.4 MFD, Replaced Fraction-1-0-0-0, Discharge 9 10-02-007M CAPAT Tachigenes Normal 36 0.0 36.4 MFD, Replaced Fraction-1-0-0-0, Discharge 10-02-007M CAPAT Tachigenes Normal 36 0.0 36.4 MFD, Replaced Fraction-1-0-0-0, Discharge 10-02-007M CAPAT Tachigenes Normal 36 0.0 36.4 MFD, Replaced Fraction-1-0-0-0, Discharge 10-02-007M CAPAT Tachigenes Normal 36 0.0 36.4 MFD, Replaced Fraction-1-0-0-0, Discharge 10-02-007M CAPAT Tachigenes Normal 36 0.0 36.4 MFD, Replaced Fraction-1-0-0-0, Discharge 10-02-007M CAPAT Tachigenes Normal 36 0.0 36.4 MFD, Replaced Fraction-1-0-0-0, Discharge 10-02-007M CAPAT Tachigenes Normal 36 0.0 36.4 MFD, Replaced Fraction-1-0-0-0, Discharge 10-02-007M CAPAT Tachigenes Normal 36 0.0 36.4 MFD, Replaced Fraction-1-0-0-0, Discharge 10-02-007M CAPAT Tachigenes Normal 36 0.0 36.4 MFD, Replaced Fraction-1-0-0-0, Discharge 10-02-007M CAPAT Tachigenes Normal 36 0.0 36.4 MFD, Replaced Fraction-1-0-0-0, Discharge 10-02-007M CAPAT Tachigenes Normal 36 0.0 36.4 MFD, Replaced Fraction-1-0-0-0, Discharge 10-02-007M CAPAT Tachigenes Normal 36 0.0 36.4 MFD, Replaced Fraction-1-0-0-0, Discharge 10-02-007M CAPAT Tachigenes Normal 36 0.0 36.4 MFD, Replaced Fraction-1-0-0-0, Discharge 10-02-007M CAPAT Tachigenes Normal 36 0.0 36.4 MFD, Replaced Fraction-1-0-0-0, Discharge 10-02-007M CAPAT Tachigenes Normal 36 0.0 36.4 MFD, Replaced Fraction-1-0-0-0-0-0, Discharge 10-02-007M CAPAT Tachigenes Normal 36 0.0 36.4 MFD, Replaced Fraction-1-0-0-0-0-0-0-0-0-0-0-0-0-0-0-0-0-0-0-
LAMBERYSHAM 16440 9202021 34-6	\$\begin{array}{cccccccccccccccccccccccccccccccccccc
Second Control Contr	\$ 1 250554 M 1000 CD Tultymes Normal 20 13 25 FT CD 100 FT M Administration 100 FT M
Université Numerade 20045 (10/2020) 23 261-1-34 (2000 Fermale 1000 23 10/2010 2000 AGA 1 1 YES No No NO NO No No No ACESAREAN (Lixeri shramanga 20 4006 (2012/2022) 23 261-1-34 (2010 PM Fermale 1205.0 23 10/01 to 15/00 AGA 2 1 YES No No NO NO NO No No No ACESAREAN (Charamana 24/2000 11/21/2021 23 261-1-34 (2010 PM Fermale 1205.0 23 10/01 to 15/00 AGA 1 1 YES No No NO NO NO NO No No No ACESAREAN (7 8 25/00/09/07/07/07 P Telephone Normal 30 13 34 AGO 99/09/09/07/07/09/07/09/07/09/07/09/07/09/07/09/07/09/07/09/07/09/09/07/09/07/09/07/09/07/09/07/09/07/09/07/09/07/09/07/09/07/09/07/09/07/09/07/09/07/09/07/09/07/09/07/09/09/07/09/07/09/07/09/07/09/07/09/09/09/07/09/07/09/09/09/07/09/07/09/09/09/09/09/09/09/09/09/09/09/09/09/
Saint Develop 100-110021 100-110021 14-2 34-5-106-6 12-100-0 M Female 2000.0 34 100-110021 15-2 1 No	\$ 1 1.05 1.0
Shipa Gururaj Palil 112075 7/16/2021 34 30+1-34 11:05:00 AM Female 1610.0 34 1500 to 2000 AGA 4 2 2 YES No No NO NO NO No CAESAREAN 3	1 1 1 1 1 1 1 1 1 1
Binnilla minisulfarea 175136 9892021 22 20+1-34 2-2200 PM Marie 20000 23 1500 to 2000 AGA 1 1 No No No NO NO No No No ASSASSAN I I Visinhari ativirale 98022 7302021 20 28-30 21:000 PM Female 1800.0 20 1500 to 2000 AGA 4 2 2 No	7 5 100007M HFRC Tandports Normal 34 27 25 10 AFF C 19 10 10 10 10 10 10 10 10 10 10 10 10 10
Shruth pandre 178889 9772021 30-5 24_1-104-0 2-45009 MM Male 18000 20 150010-2000 AGA 4 3 2 No No No NO NO NO NO NO CASSAREAN I Ships 56449 51512021 30-5 20-30 4:1000 MM Male 17500 20 150010-2000 AGA 2 1 1 No No YES NO NO NO NO CASSAREAN I	8 9 150/200 AM CPAP Tachypnes Normal 34 07 25:1 Special Feature (2015) yes Advandare 1000 286/00 75 62 74 262:166 40 64 55 83 No Pendade No Petas Paptar, Arriskon No no no 40 Discharge 16 4 LVVIL(10) Tachard 70 9 510/00/2019 CPAP Tachard 10 10 10 10 10 10 10 10 10 10 10 10 10
Depts 4544 912207 3-1- 2332 41550 70 Mars 1754 20 1000 20 20 45 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	7 9 100:00 PM CTAP Tachigenea Normal 30 109 351 FM COCO DEVENTECULAR FUNCTION yes Amenise 300: 154-000 67 62 232 337 163 60 77 46 -7.6 Yes Cloical Yes Circle Spain, Archigenea Normal 32 102 342 PMA yes Amenise 300 154-000 387 66 730 22 17 35 10 8 22 15 14 8 NO Perbabble No Perb
Yammentidri 16889 101/12021 34 201-24 13/200 M Mais 22000 34 2001/12/2400 AGA 3 2 2 No NO <t< td=""><td>6 2 3200 MB SINY 3 recommendating serving format 3 4 15 MB AFF (0.0000 MB CHINGTON) 15 of the F (300 34000 MB CHINGTON) 15 of the F (300 3</td></t<>	6 2 3200 MB SINY 3 recommendating serving format 3 4 15 MB AFF (0.0000 MB CHINGTON) 15 of the F (300 34000 MB CHINGTON) 15 of the F (300 3
200 200	\$ 1 (1000/04) (1000/02) Temples Serial 34 (8) (1000/04) (10000/04) (1000/04) (1000/04) (1000/04) (1000/04) (1000/04) (1000/04) (10
Ummars 200641 16/20201 33 261-34 80/00/04 Femile 18/00 31 261-3200 AGA 1 No. No. No. No. No. No. No. No. No. CASSAREAN (\$ 1 0000 MM 1000 CQ Transpares Name 2 1 12 81 05 MC 97 CQ MS 100 MM 1000 CQ Transpares Name 2 1 12 81 05 MC 97 CQ MS 100 MM 1000 CQ Transpares Name 2 1 12 81 05 MC 97 CQ MS 100 MM 100 CQ Transpares Name 2 1 12 81 MS 10 MC 97 CQ MS 100 MM 10
	1
April 1/1/2/2012 April 1/1/2/2012 April 1/1/2/2012 April 1/1/2/2012 April 1/1/2/2012 April 1/1/2/2012 April	7 8 1 058209M CPF Tangjens Nemal 2 0 7 16 705409M CPF Tangjens Nemal 2 0 7 16 70 70 70 70 70 70 70 70 70 70 70 70 70
Suiss 118112/2 7/22/2021 20+1 20+1-24 6-45/00 PM Marke 1100.0 30 100110 1500 AGA 1 No	7 5 7 CHICATRIC COMP Tanglemen Normal 20 67 224 FTG me Advanctive 450 20000 45 75 7.0 16 55 20 16 27 8 16 Particular Value Class Personal Value Class Advanctive Normal 20 17 224 FTG me Advanctive 450 20000 45 75 7.0 16 55 20 18 27 8 18 Particular Value Class Advanctive Normal 20 18 23 21 FTG Value Class Advanctive Normal 20 18 23 21 FTG Value Class Advanctive Normal 20 18 23 21 FTG Value Class Advanctive Normal 20 18 23 21 FTG Value Class Advanctive Normal 20 18 23 21 FTG Value Class Advanctive Normal 20 18 23 21 FTG Value Class Advanctive Normal 20 18 23 21 FTG Value Class Advanctive Normal 20 18 23 21 FTG Value Class Advanctive Normal 20 18 23 24 FTG Value Class Advanctive Normal 20 18 23 24 FTG Value Class Advanctive Normal 20 18 23 24 FTG Value Class Advanctive Normal 20 18 23 24 FTG Value Class Advanctive Normal 20 18 23 24 FTG Value Class Advanctive Normal 20 18 23 24 FTG Value Class Advanctive Normal 20 18 23 24 FTG Value Class Advanctive Normal 20 18 23 24 FTG Value Class Advanctive Normal 20 18 23 24 FTG Value Class Advanctive Normal 20 18 23 24 FTG Value Class Advanctive Normal 20 18 23 24 FTG Value Class Advanctive Normal 20 18 23 24 FTG Value Class Advanctive Normal 20 18 23 24 FTG Value Class Advanctive Normal 20 18 24 25 25 25 26 26 26 26 26 20 27 28 28 28 28 28 28 28 28 28 28 28 28 28
2006 11/10/201 26 -28 12/10/201 26 -28 12/10/2014 Feminic 2010 26 -200 56 -100 56 A 1 10 10 10 10 10 10 1	7 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1
This 2 1584 (1912)227 3-14 (1912)237	1 1 1 1 1 1 1 1 1 1
Jupil Basera Meni 240201 11/10/2021 23-45 30-1-34 625/00 MM Meni 20210 231 100010 2000 AGA 3 1 1 175 No	7 9 6400 PM GPM PM GPM PM GPM PM GPM GPM GPM GPM
Manushoti 19801 877001 30 26-30 400.00 FM Femile 1500.0 30 1500 1200 AAA 3 1 1 1755 No. NO. NO. NO. NO. NO. NO. ASSARCAN 1 50 10 10 10 10 10 10 10 10 10 10 10 10 10	7 6 6000 PM CPM 1 1.00 pm 2 1.00 pm
Subsection 227288 1930/2021 29 32-39 42/0000 PM Fernate 10/10 29 10/10 10/10 AGA 1 NO	6 8 \$22000940 [2997 188599688 Normal 22 017 33.4 FMR Male yes Administed \$500 227000 c5 78 [2.44 15.3 196 40 13 2 17.1 Yes Uniting No Unit register No 0.0 yes 2.0 Locating 15 6 \$425542 [-1.0] Decision 7.9 \$1000040 \$5000 \$500 \$1.7 2.0 1.2 1.2 No Clinical No. On 0.0 72 Unitensity 15 6 \$425542 [-1.0] Decision 7.9 \$1000040 \$5000 \$1.7 2.0 1.2 No Clinical No. On 0.0 72 Unitensity 15 6 \$425542 [-1.0] Decision 7.9 \$1000040 \$5000 \$1.7 2.0 1.2 No Clinical No. On 0.0 72 Unitensity 15 6 \$425542 [-1.0] Decision 7.9 \$1000040 \$5000 \$1.7 2.0 1.2 No. Clinical No. On 0.0 10 \$1.0 No. Clinical No. On 0.0 No.
Valuati 147400 01770221 50 38-30 1111505PM Maie 10000 30 107116-1500 AGA 1 No	5 7 - 01500FM SMV 2 Temperas Numeral 30 07 355 FFG 98 absolute 100 00 00 00 00 00 00 00 00 00 00 00 00
Venna 250499 11/12/2021 23 20+1-24 11:46:00 AM Marke 1540.0 23 150500-2020 AGA 1 No No NO NO NO NO NO ACEGAREAN 7 Pogla Dadamani 250822 7/14/2021 21+4 25:00 AM Female 1600.0 34 103/10.1500 5GA 4 2 No No NO NO NO NO ACEGAREAN 7	7 9 124600-MA CPAP Tachyposas Normal 24 0.8 254 PDA, PCQ. PM Severe yet Administre 13310 191000 7.8 153 7.39 21.4 176 49 18 34 4.5 Vet Clinical No. Clinic Piptur no. no. 22 Discharge 5 2 LEVEL 1 (+0.5) Discharge 7 9 45600-MA CPAP Tachyposas Normal 24 0.7 23.3 PDA, ADS, COCO BINNETRICULAR FUNC yet 250000 29 80 7.42 257.1 18 40 17 4.5 7.4 Vet Clinical No. Clinic Piptur no. no. no. 40 Discharge 9 5 LEVEL 1 (+0.5) Discharge 1 10 10 10 10 10 10 10 10 10 10 10 10 1
Tejashwisi bajamid 256820 11/16/2021 34 30+1-34 12:2800PM Male 2000.0 34 1505 0:2000 AGA 2 1 1 No	7 9 2:31:00PM HODO 02 Tachpysea Normal 22 08 8.57 PDA, PTQ, PAM Moderate yes Departine 11910 38600 214 72 723 33.2 150 40 17 44 34 Yes Clinical No Clinic Piptax, Avisable No no no 86 Discharge 9 3 LEVEL (1-6), 9 Clinical No Clinic Piptax yes 1 no no 70 Discharge 5 11 LEVEL (1-6), 9 Clinical No Clinic Piptax yes 1 no no 70 Discharge 5 11 LEVEL (1-6), 9 Clinical No Clinic No Clinic Piptax yes 1 no no 70 Discharge 5 11 LEVEL (1-6), 9 Clinical No Clinic Piptax yes 1 no no 70 Discharge 5 11 LEVEL (1-6), 9 Clinical No Clinic Piptax yes 1 no no 70 Discharge 1 no no 10 Discharge 1 no no no 20 Discharge 2 no no no no 20 Discharge 2 no no no no 20 Discharge 2 no no no no 20 Discharge 2 no no no 20 Disch
Pogli Dodamani 256021 11/18/2021 34:3041-34 2:54:00/AN Femule 2000.0 34:15:00:2000 AGA 4 2 No No No NO NO NO NO NO CAESAREAN 1 Kasturibai 197207 07:25/2021 22:41 204:1-34 2:2000.0 M Maile 2000.0 22:200110:2400 AGA 2 1 1 YES No No NO NO NO NO NO CAESAREAN 1	7 9 25430/MICPAP Tachyponas Normal 24 0.8 83.2 PDA,PAH MId ys Adessaline 7800 216500 7 58 7.56 3.04 95 40 17 7.1 7.5 Yes Clinical No Clinic Pipazz No no yss 75 Clinicatege 10 3 LEVEL 1(0.9) Discharge 10 4 LEVEL 1(0.9) Discharg
Sunha-chavan 118112 7/27/2021 22 30-1-34 84:50 6AM Male 1103.0 32 100 1 0:1500 SGA 1 No	6 8 94500AM CPAP Tachipness Normal 22 0.7 324.9FD yes Departins, A 4860 315000 c5 76 7.37 30.9 10.0 40 16 8.1 6.6 Yes Cilicia Yes Cilicia Yes Cilicia No no no 48 Dicherbage 8 6 LEVEL2(4-10) Decharged A 1870 2 10 Decharged A 1870 2 10 Decharged A 1870 2 10 Decharged A 1870 2 Dicharged 7 5 LEVEL2(4-10) Decharged A 1870 2 Dicharged A 1870
Shirdowi 133983 78/2021 23-6 30-1-34 92/30 PM Female 2000.0 33 2001 02-890 SGA 4 3 1 No No NO NO NO NO NO NO NORMAL VAGINAL 10-50 Startisticated 10-9107 70/4/10/001 91-55 NO. NO NORMAL VAGINAL 10-910 NO NO NORMAL VAGINAL 10-910 NO NORMAL VAGINAL 10-910 NORMAL 10-910	7 8 12550544 HFEC 14 April 20 11 12 61 Yes Closed 10 11 12 61 Yes Cl
Gardeal 212500 0514/2022 23-5 30-1-34 52000 AM Female 1900 33 1507 02000 5GA 3 2 No No NO NO NO NO NO NO CASSAREAN 3 50-0-10 1750 0511000 11 10 10 10 10 10 10 10 10 10 10 1	7 9 \$1800 MM 1000 00 Tangeness Normal 34 67 32.7 970 No Adenvillo 1661 27700 18 70 23.22 157 40 11 56 154 Vac Clinica No Clinic Polyse no no 70 Distatege 8 4 LEVEL1 (1-50 Distance) 6 1 LEVEL1 (1-50 Distance) 7 9 5 1800 M 1000 00 Tangeness Normal 35 11 56 8 PM No no no 00 Distance) 8 5 LEVEL1 (1-50 Distance) 7 9 5 1 LEVEL1 (1-50 Distance) 7 9 7 9 7 9 7 9 7 9 7 9 7 9 7 9 7 9 7
Register Proceedings Procedings Proceedings Procedings Proceedings Procedings Proceedings Proceedings Proceedings Proced	1
Puller 17 22581 1020/020122+6 30-1-3 40-1-000 20 150/00 2000 AGR 3 2 2 No No No No NO NO No ACRESTREN 7	7 1 100 20 1 1 1 1 1 1 1 1 1
Sunthia Suntana Suntan	6 9 MM 7 Increased organic registrates 2 6 M 5.1 PFO No other 800 \$3000 8 F 4 7.31 \$2.0 5 M 70 10 12 11 16 NO Cincia No Cinca Ambient, Meropere No no yet 3 Gazterpey 10 4 LVVX.1 (1-60 States) 10 10 10 10 10 10 10 10 10 10 10 10 10
RESERVINGACIONESSE CONTROL 2017 2 2011-194 TOTOLOGO AND MESSE TRECO 21 TOTOLOGO 2000 AND 2 TES NO NO NO NO NO NO NO NO AND AND NO NO AND	7 9 2000-MI CPAP Tachypeas Narmal 34 0 1 52.976A No clares 1020 15700 Leastheas 64 732 28.1 100 20 M 25 73 No Clares Vers Click Plaza Merganes No no yes 65 Dachage 0 4 LEVEL (10-0) Decarge 10 70 100-2004 CPAP Tachypeas Narmal 34 0 7 M 970, NO MId No clares 1100 26000 20 12 No 72.0 28.0 100 20 M 25 77 6 54 ves Clicke No Prove Plaza Ankadon no no 55 Dachage 0 4 LEVEL (10-0) Decarge 10 M 12 Ves Clicke 10 No 100 100 NO 100
Silipa yearsig pasili 112075 7/102221 23-4 30-1-1-24 1100500/AM Femille 10030 23 150010:2000 SGA 4 2 2 1 YES No NO NO NO NO NO NO CAESAREAN 7 2 Managabiliyas milli 17505 05 611/10201 23-4 30-1-24 61500 AM Managabiliyas milli 17505 05 611/10201 23-4 3 2 No YES YES NO NO NO NO NO NO CAESAREAN 1	6 S SW 7 Insulant Agency 18 Long 1 S SW 7 Insulant Agency 18 Long 1 S SW 18 SW 7 Long Agency 18 Long 1 S SW 18 SW
	1
Strukh Wan jeli 200660 11/19/2021 27-44 - 28 100:200.AM Femule 880.0 27 - 100.9 5GA 1 No	6 8 500005AM CPAP Techpones Normal 20 07 22A FPC No 100 2400000 65 61 744 289 150 019 13. 4 N ye Clinical No Prow Piptatz No no no 27 Distributes 21 10 LUTXLI[4-10] Distributes No no no 10 LUTXLI[4-10] Distributes No Prow Piptatz No no no 28 Distributes 21 LUTXLI[4-10] Distributes No Prow Piptatz No no no 28 Distributes 21 LUTXLI[4-10] Distributes No Prow Piptatz No no no no 28 Distributes 21 LUTXLI[4-10] Distributes No Prow Piptatz No no no no 28 Distributes No Prow Piptatz No no no no 28 Distributes No Prow Piptatz No no no no 28 Distributes No Prow Piptatz No no no no 12 Distributes No Prow Piptatz No no no no 12 Distributes No Prow Piptatz No no no no 12 Distributes No No no no no 12 Distributes No No no no no no 12 Distributes No
Chandra San Mark 172026 1992011 32 (24-1-24 E-2000 MJ Frande 2000) 34 (201-1-240) AGA 2 1 No No No NO NO No No No CHANCANNO NO	6 9 1000003ML CPAP Tachigeneas Normal 30 08 342 AGD yes Advancation 7070 201400 Least tents 96 7.35 346 84 20 19 2.5 54 No Proven No Prove Pigaza No no no 36 Discharige 26 5 LEVEL 1(-)65 Discharige 27 1000 2014000 7.5 02 7.4 46.2 64 20 10 9 4.5 3 3 No Proven No Prove Pigaza No no no 36 Discharige 46 LEVEL 1(-)65 Discharige 10 1000 2014000 7.5 02 7.4 46.2 64 20 10 9 4.5 3 3 No Proven Pigaza No no no 36 Discharige 46 LEVEL 1(-)65 Discharige 10 1000 2014000 7.5 02 7.4 46.2 64 20 10 9 4.5 3 3 No Proven Pigaza No no no 36 Discharige 46 LEVEL 1(-)65 Discharige 10 1000 2014000 7.5 02 7.4 46.2 64 20 10 9 4.5 3 3 No Proven Pigaza No no no 36 Discharige 10 1000 2014000 7.5 02 7.4 46.2 64 20 10 9 4.5 3 3 No Proven Pigaza No no no 36 Discharige 10 1000 2014000 7.5 02 7.4 46.2 64 20 10 9 4.5 3 3 No Proven Pigaza No no no 36 Discharige 10 1000 2014000 7.5 02 7.4 46.2 64 20 10 9 4.5 3 3 No Proven Pigaza No no no 36 Discharige 10 1000 2014000 7.5 02
September Sept	7 1 2000070 CR9
Jupit sender 187756 1972/2021 324-4 304-1-34 44509-MM Mais 1500.0 32 1001 to 1500.0 AGA 3 2 No	Section 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1
Nesis Bard juster 133788 877322 22-6 26-1-34 620 03/M Mars 2240 2 2001 2240	6 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Sight management 274000 1002071 371-3 336-1-34 27300 FM Femilia 11000 500 50 A6A 3 1 100 100 100 100 100 100 100 100 100	7 10 20 20 20 20 20 20 20
Sant material rate (1992) 27 (2002) 19 2 3 3 3 3 4 5 4 5 5 5 5 5 5 5 5 5 5 5 5 5	1
Surith survein Cellar 1811/2/2 7/22/2021 21+3 30+1-34 8-45/00 AM Male 1103/0 31 1001 10 15/00 AGA 1 No	7 5 1 0000M CP9 Tadgers Normal 20 07 2219°C yes Annullis 400 20000 5 7 7 7 7 0 1 15 14 20 21 15 15 15 15 15 15 15 15 15 15 15 15 15
Santa	
Contract Assessment 17555 1900	4 1 10 10 10 10 10 10 10
AND ADDITIONAL OF THE SECOND AND ADDITIONAL	TO POLYPOLICE TO SERVICE THE PROPERTY OF THE P